BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or payper-view fees (<u>http://bmjpaedsopen.bmj.com</u>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email <u>info.bmjpo@bmj.com</u>

Bowel preparation for elective procedures in Children: A Systematic Review

Journal:	BMJ Paediatrics Open
Manuscript ID	bmjpo-2017-000118
Article Type:	Original article
Date Submitted by the Author:	29-May-2017
Complete List of Authors:	Gordon, Morris; University of Central Lancashire, Karlsen, Fiona; Blackpool Victoria Hospital Isaji, Sahira; Blackpool Victoria Hospital Teck, Guan-ong; Blackpool Victoria Hospital
Keywords:	Evidence Based Medicine, Gastroenterology



Bowel preparation for elective procedures in Children: A Systematic Review

Morris Gordon (1,2), Fiona Karlsen (2), Sahira Isaji (2), Guan-ong Teck (2)

- 1. School of Medicine and Dentistry, University of Central Lancashire, Preston UK
- 2. Department of Paediatrics, Blackpool Victoria Hospital, Blackpool, UK

Contact information :

Dr Morris Gordon

HA118 Harrington building

University of Central Lancashire

Preston

UK

Email: mgordon@uclan.ac.uk

Phone ++44 1253 300000

Word count: 2526

Keywords: Bowel preparation, Bowel clearance, colonoscopy, systematic review

Funding: None

What is known about the subject

- Bowel preparation is vital to imaging and surgery in young people, but it is key to consider tolerability as well as efficacy in these patients
- Previous systematic reviews have only considered preparation for imaging and limit the age range, despite paediatricians often caring for children till older.

What this study adds

- Despite many trials, there is much clinical heterogeneity and risk of bias concerns with the evidence base, as well as poor safety and tolerability reporting.
- There is evidence that PEG regimens are effective. However, when compared, sodium picosulphate appeared better tolerated with no difference in efficacy.
- Future research needs to address these key methodology issues and also consider safety and tolerability, as well as efficacy.

Abstract

Objective: Adequate bowel preparation is crucial for both surgery and imaging in young people. Whilst systematic reviews have considered preparation for colonoscopy, they do not consider surgical interventions and to the age of 16, despite it being normal practice for paediatric gastroenterologists to care for transitioning children till older. We carried out a systematic review investigating the optimum bowel preparation agents for all indications in children and young people.

Design: A Cochrane format systematic review of randomised controlled trials (RCTs). Data extraction and assessment of methodological quality were performed independently by two reviewers. Methodological quality was assessed using the Cochrane risk of bias tool.

Patients: Young people requiring bowel preparation for any elective procedure, as defined by the primary studies.

Interventions: RCTs comparing bowel preparation with placebo or other interventions.

Main outcome measures: Adequacy of bowel preparation, tolerability and adverse events.

Results: The search yielded 2124 results and 15 randomised controlled studies (n = 1435), but heterogeneity limited synthesis. Meta-analysis of 2 studies comparing PEG with sodium phosphate showed no difference in the quality of bowel preparation (RR 1.27 [95% CI, 0.66-2.44]). Two studies comparing sodium picosulphate / magnesium citrate with PEG found no difference in bowel preparation, but significantly higher number of patients needing nasogastric tube insertion in the PEG-ELS (RR 0.04 [95% CI, 0.01-0.18]). Meta-analysis of 3 studies (n = 241) found no difference between PEG and Sennasoids (RR 0.73 [95% CI, 0.31-1.71]).

Conclusions: The evidence base is clinically heterogeneous and methodologically at risk of bias. There is evidence that all regimens are equally effective. However, sodium picosulphate was better tolerated than PEG. Future research is needed with all agents and should seek to consider safety and tolerability, as well as efficacy.

Background:

Bowel imaging is a crucial modality in the diagnosis and monitoring of Inflammatory Bowel Disease (IBD), as well as surgery frequently being required in such patients. Multiple studies have suggested that bowel preparations must be individually tailored according to patient age, size and clinical status.¹ However, currently there is no internationally recognised gold standard regimen for paediatric bowel preparations.² Several regimens have been tried with the aim of identifying the safest, efficacious and tolerable combination, with varying success.³

Bowel preparation regimens can be based on lavage (bowel clean out) or cathartics (agents that accelerates defecation). Examples included; large volume of polyethylene glycol-electrolyte (PEG-ELS) lavage solution, sodium phosphate (an oral, low-volume, hyperosmotic agent), sodium pico-sulphate, bisacodyl and dietary measures, such as diet packs or clear liquid diets (often in combination with other agents).

Adequate bowel preparation prior to such procedures is crucial to ensure complete visualisation of the colonic mucosa (thus successful diagnostic and therapeutic colonoscopy, endoscopy and capsule endoscopy) and to minimize the risk of possible contamination during surgery. Administration of the agents is much more problematic in children compared to adults who manage to take the agents readily. In un-cooperative children, use of a naso-gastric tube to administer the agents has been reported to be an effective method to guarantee bowel wash out.⁴ Reduced tolerance can result in poor outcomes due to inadequate preparation, increased rate of complications, extended procedural time and missed lesions.³ Additionally, side effects have previously been noted, such as hyperphosphataemia in children who receive sodium phosphate.⁴

Whilst previous reviews have considered preparation for colonoscopy³, they do not always consider surgical interventions and often limit their populations at the age of 16, despite it being normal practice for paediatric gastroenterologists over several years to adult services.⁵

We carried out an up to date systematic review using the Cochrane collaboration format to summarise the available evidence investigating the optimum bowel preparation agents for all indications in children and young people.

The objectives of this review were to evaluate the efficacy and safety of different bowel preparation for young people for any indication. A full protocol for the study was completed by the authors prior to commencement of the study and is available on request.

Criteria for considering studies for this review

RCTs were included in this systematic review. Participants were aged 0 to 21 years. This age range was selected after a scoping search and discussion with local stakeholders confirmed that it can be normal practice in pediatric gastroenterology for these patient groups to have variable transition to adult services, but 21 years was agreed as an absolute cut off and reflected several studies that would otherwise be excluded. Studies compared bowel preparation with another bowel preparation or placebo, with all forms and dosing regimens considered. The primary outcome measure for the studies was the number of adequate bowel preparations, as defined by the included studies. Secondary outcomes included: tolerability, Duration of procedure, Missed lesions due to inadequate bowel preparation and occurrence of any adverse events.

Search methods for identification of studies

Electronic searches (search strategy not limited by language) were completed of MEDLINE, The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and CINAHL (Inception-15 July 2016), Appendix 1. References of included trials were also searched. Manufacturers were contacted to identify further negative and unpublished research. Abstracts were considered for inclusion if full details to judge inclusion were offered or available from the authors after contact by the study team.

Data extraction and assessment of methodological quality of included studies were independently performed by 2 authors and disagreements solved with involvement of the third author.

Data collection and analysis

All identified abstracts and results from searches were reviewed by the authors. If the reference appeared relevant, a full copy of the study was obtained. After reading the full texts, each author independently assessed the eligibility of all trials identified based on the inclusion criteria above.

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

Disagreement among authors was discussed and agreement reached by consensus. If the data to judge inclusion were unclear, attempts were made to contact the authors.

A data extraction form was developed and piloted to extract information on relevant features and results of all primary and secondary outcomes of included studies. The two reviewers separately extracted and recorded data on the predefined checklist, with disagreement discussed and consensus reached.

The risk of bias of selected trials was assessed independently by the authors using the Cochrane risk of bias tool with disagreement once again resolved by reaching consensus. Study authors were contacted for further information when insufficient information was offered to judge risk of bias or data were missing for primary outcomes. Analysis was completed using Revman (Review Manager 5.2, V.5.2.9, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2012).

The primary outcome—efficacy of bowel preparation agents—was assessed using the mean difference (MD) with 95% CI. The secondary outcomes were assessed by calculating the risk ratio (RR) and 95% CI or the MD with 95% CI, as indicated. The authors of included studies were again contacted to supply any missing data. Heterogeneity among trial results was assessed by inspection of graphical presentations and by calculating the χ^2 test of heterogeneity (a p value of 0.10 was regarded as statistically significant). We also used the I2 statistic to quantity the effect of heterogeneity.12 A random-effects model was used, with a sensitivity analysis with the fixed-effects model, to identify differences in results that would suggest heterogeneity.

Results:

The electronic database search identified 2124 studies that were screened for inclusion. Of these, 15 studies (n = 1435) were judged to be potentially relevant and subjected to full text review (Figure 1). Experts were contacted, but no extra reports were received and no further studies were identified from drug companies.

Description of studies

Nine reports were excluded for failing to meet the inclusion criteria. Five were not solely with patients under 21 years of age, three were not RCTs and one was an abstract with insufficient data to judge inclusion. The 15 RCTs included described various regimens and comparative agents (Table 1). Four studies compared various different regimens and combinations of PEG, Two compared polyethylene glycol (PEG) with oral sodium phosphate, two compared PEG with Normal Saline, three compared multiple combinations of PEG, sennasoids and sodium picosluphate, two diet kits with sodium phosphate, one study compared sodium picosulphate with phosphate enemas and one sodium picospulphate with PEG.

Risk of bias of included studies

Seven studies were rated as low risk for random sequence generation (selection bias) because these studies employed computer-generated randomisation. The remaining studies described themselves as randomised but, with no further details given or available from authors, were rated as unclear risk of bias.

Five studies were rated as low risk of bias for allocation concealment (selection bias). Nine remaining studies were rated as unclear risk of bias for allocation concealment as the methods were not clearly described in the manuscripts. One described the allocated researcher as performing colonoscopies and was rated as high risk.

Ten studies were blinded and were judged to be at low risk of bias for blinding of personnel (performance bias) for such an intervention. Four studies described themselves as blinded, but gave no further details so was rated as unclear risk of bias. One study was open-label and judged to be at high risk of bias for blinding.

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

Eight studies reported full and appropriate data and satisfactorily documented withdrawals and dropouts and were therefore judged to be at low risk of bias for incomplete outcome data (attrition bias) and nine were judged as low risk for selective reporting (reporting bias). Two studies did not record full data for all patients and were judged high risk of bias for attrition bias. Four studies did not offer outcome data regarding side effects and tolerability so were judged at high risk for reporting bias.

All studies were judged to be at low risk for other sources of bias. However, the small sample sized of many of these studies is concerning, suggesting they were pilot or similarly underpowered studies, raising a further concern regarding bias. Details are summarised in Table 1.

The 15 studies present significant clinical and methodological heterogeneity (Table 1) and this severely limits the scope for synthesis.

PEG vs Sennasoids

Meta-analysis of 3 studies $(n = 241)^{6.7.8}$ found no difference between polyethylene glycol (PEG) and Sennasoids in adequate bowel preparation (RR 0.73 [95% CI, 0.31-1.76], Figure 2). Data regarding tolerability and safety was not presented to allow synthesis.

Sodium picosulphate and magnesium citrate versus polyethylene glycol-electrolyte lavage solution (PEG-ELS)

Within these two studies versus PEG-ELS^{9,10}, equivocal adequacy of bowel preparation was seen (RR 0.99 [95% CI, 0.89-1.11], Figure 3). PEG's acceptability was reportedly poorer than sodium picosulphate in both studies. Meta-analysis of two PEG-ELS studies using the random effects model found a significantly higher number of patients needing nasogastric tube insertion in the PEG-ELS group than the sodium picosulphate group (RR 0.04 [95% CI, 0.01-0.18], Figure 4).

One patient in the PEG-ELS group and one in the sodium picosulphate group in the two studies were assessed as dehydrated and required intravenous (IV) fluids. For the PEG-ELS patient, a 10-year-old girl is reported who required intravenous fluid for 6 hours because of lethargy and dehydration (dryness of the oral mucosa and orthostatic hypotension) with serum electrolyte and glucose serum levels within the normal range. For the child in the sodium picosulphate group, a 12-year-old girl is reported that required intravenous fluids for 2 hours due to mild lethargy post procedure and was discharged well thereafter. Her vital signs were always within normal limits, but her serum osmolality

BMJ Paediatrics Open

was 316 mosm/L; she had drunk only two glasses of apple juice during the entire duration of the bowel cleanout. No other serious adverse events were noted.

PEG vs Normal Saline

Meta-analysis of 2 studies (n = 125) comparing PEG with normal saline^{11,12} found no difference in rate of adequate bowel preparation (RR 0.95 [95% CI, 0.87-1.04], Figure 5). Adverse events were not reported homogenously to allow analysis, but occurred in both groups, including abdominal pain and vomiting.

PEG vs Sodium phosphate

There were two studies concerning 63 participants.^{4,13} Meta-analysis of 2 studies using the randomeffect model found no difference in the adequacy of bowel preparation (RR 1.27 [95% CI, 0.66-2.45], Figure 6). One of the studies needed to insert a nasogastric tube in all patients receiving PEG, while in the remaining study, 53% of participants in the PEG group were unable to finish taking the solution whilst all the patients in the sodium phosphate group could complete the medication. As these were reported differently, no meta-analysis was performed. No serious adverse events were reported.

Other studies

Within the remaining studies^{1, 14-18} no meta-analysis was possible. However, no individual study found any different in adequacy of bowel preparation or adverse events. Tolerability was not well reported across studies. Whilst secondary outcome analysis for further items were planned, data was not presented to allow this to take place.



Discussion:

Despite the common requirement for bowel preparation in young people, the results of this review have highlighted a very poor evidence base. A mixture of clinical heterogeneity related to multiple agent regimens and methodological heterogeneity limiting the ability for meta-analysis has significantly limited synthesis. In multiple small analyses, PEG-ELS, Senna, Normal Saline, Sodium phosphate and Sodium picosulphate / Magnesium citrate found no difference in adequacy of bowel preparation. This was similar across the remaining individual studies. As such, despite the significant weaknesses of the evidence base, it is worth noting that no difference in adequacy of bowel preparation has been reported in any included study. This was also the case with adverse events, although it must be noted these were reported in an extremely heterogeneous fashion, with individual minor, major and patient overall recording of events across studies.

Of note, there was a significant difference in favour of sodium pico-sulphate and magnesium citrate regarding tolerability, specifically the need for a nasogastric tube to complete the bowel preparation. This is a particularly interesting finding, as the primary studies highlighted that whilst tolerability of PEG was extremely poor, smaller volumes than planned appeared to have little impact on efficacy. This raises the question of the need for the nasogastric tube at all and so this may need further investigation in the future. Sodium pico-sulphate was also compared to bisacodyl and a phosphate enema in a single study with equivocal preparation, tolerability and safety reported.

PEG appeared to be the least tolerable agent across all studies - with a number of the patients requiring a nasogastric tube insertion, but this is from qualitative synthesis of individual studies, with this outcome reported in heterogeneous fashion so meta-analysis was not possible. Oral sodium phosphate was well tolerated in individual studies. Despite the satisfactory tolerability and safety profile of sodium phosphate, it should be noted that care must be taken when using this agent as it can cause significant electrolyte imbalances. As such, it should not be used in patients with deranged baseline electrolytes, suboptimal renal and hepatic function, as it poses a risk of acute kidney injury and phosphate nephropathy.¹⁹

With all the agents studied the occurrence of minor adverse events such as abdominal pain, bloating, faecal incontinence, nausea, vomiting, headaches and anal irritation was comparable. No serious adverse events were reported in any of the studies.

BMJ Paediatrics Open

The evidence base for this review covers a large number of trials with a reasonable number of patients, but is severely limited due to clinical and methodological heterogeneity, as well as concerns with risk of bias. As such, the findings of this review should be interpreted with extreme caution as it is difficult to draw firm conclusions for any of the investigated agents. it must also be noted that for the primary outcome, successful bowel preparation was 'as defined' by primary studies, with several different scoring systems and criteria used. This also limits the appropriateness of meta-analysis in this context. This is also true of adverse events, which were reported in a sporadic and inconsistent manner that prevented comment on even simple complaints, such as nausea or vomiting.

Considering the small sample sizes, the high degree of heterogeneity and a wide variation in the regimen of each cleansing agent; the findings of this review cannot be reliably used to inform clinical practise, but most usefully should inform future research. In particular, as the question of adequacy of bowel preparation has been established as essentially equivocal amongst all study agents, a shift of focus for future studies is needed. Given the unique needs of a paediatric population, considering the issue of tolerability as a primary outcome is vital and looking at the lower volume options presented as enteral agents could offer potential practical advantages and need a high quality study to investigate them.

Conclusions:

The publishing evidence base investigating this issue is large, but is clinically heterogeneous and at risk of bias. All regimens appear equivocal for adequacy of bowel preparation. However, when compared with sodium pico-sulphate, sodium pico-sulphate is better tolerated. Future research should seek to consider safety and tolerability, as well as efficacy, given the key importance of these issues in a childhood population.



Figure legend

Fig 1: Patient flow diagram

Fig 2: Forest plot for PEG vs Senna, adequacy of bowel preparation

Fig 3: Forest plot for Sodium picosulphate and magnesium citrate versus polyethylene glycolelectrolyte lavage solution (PEG-ELS), adequacy of bowel preparation

Fig 4: Forest plot for Sodium picosulphate and magnesium citrate versus polyethylene glycolelectrolyte lavage solution (PEG-ELS), Tolerability of agent


Fig 5: Forest plot for PEG vs Normal Saline, adequacy of bowel preparation

Fig 6: Forest plot for PEG vs Sodium Phosphate, adequacy of bowel preparation

REFERENCES

- 1. Trautwein AL, Vinitski LA, Peck SN. Bowel preparation before colonoscopy in the pediatric patient: A randomised study. *Gastroenterol Nurs* 1996;**19**:137–9.
- Engum SA, Carter ME, Murphy D, Breckler FM, Schoonveld G, Grosfeld JL. Home bowel preparation for elective colonic procedures in children: Cost savings with quality assurance and improvement. J Pediatr Surg 2000;35:232-4.
- Pall H, Zacur GM, Kramer RE, et al. Bowel preparation for pediatric colonoscopy: report of the NASPGHAN endoscopy and procedures committee. J Pediatr Gastroenterol Nutr 2014;59:409-16.
- Gremse DA, Sacks AI, Raines S. Comparison of oral sodium phosphate to polyethylene glycol-based solution for bowel preparation for colonoscopy in children. J Ped Gastroenterol Nutr 1996;23:586-90.
- Hunter A, Mamula P. Bowel preparation for pediatric colonoscopy procedures. J Pediatr Gastroenterol Nutr. 2010;3:254-61.
- Terry NA, Chen-Lim ML, Ely E, Jatla M, Ciavardone D, Esch S, Farace L, Jannelli F, Puma A, Carlow D, Mamula P. Polyethylene Glycol Powder Solution Versus Senna for Bowel Preparation for Colonoscopy in Children. J Pediatr Gastroenterol Nutr 2013;56:215-9.
- Kierkus J, Horvath A, Szychta M, Woynarowski M, Wegner A, Wiernicka A, Dadalski M. High-versus Low-Volume Polyethylene Glycol Plus Laxatives versus Sennosides for Colonoscopy preparation in children. JPGN, Vol 57, 2. 2013.
- Dahshan A, Lin CH, Peters J, Thomas R, Tolia V. A Randomized, Prospective Study to Evaluate the Efficacy and Acceptance of Three Bowel Preparations for Colonscopy in Children. The American Journal of gastroenterology, (1999), 94.
- Di-Nardo G, Aloi M, Cucchara S, Spada C, Hassan C, Civitelli F, Nuti F, Ziparo C, Pession A, Lima M, Torre G and Oliva S. Bowel Preparations for Colonoscopy: An RCT. American academy of paediatrics. 2014;10:1542

- Turner D, Benchimol E, Dunn H, Griffith A.M, Frost K, Scaini V, Avolio J, Ling SC. Pico-Salax versus polyethylene glycol for bowel cleanout before colonoscopy in children: a randomized controlled trial. Endoscopy 2009;41:1038-1045.
- 11. Kumar A, Hussain A. Preoperative bowel preparation in children: polyethylene glycol versus normal saline. African journal of paediatric surgery. 2013:10; 235-238.
- Sinha K, Kanojia RP, Rawat JD, Wakhlu A, Kureel SN, Tandon RK, Verma A. Comparison of three solutions for total gut irrigation in pediatric patients. Pediatr Surg Int. 2007;23:581-584.
- Da Silva MM, Briars GL, Patrick MK, Cleghorn GJ, Shepherd RW. Colonoscopy preparation in children: safety, efficacy and tolerance of high-versus low-volume cleansing methods. J Ped Gastroenterol Nutr. 1997;24:33-7.
- 14. Pinfield A, Stringer M. Randomised Trial of two pharmacological methods of bowel preparation for day case colonscopy. Arch Dis Child. 1999; 80:181-183.
- 15. Najafi M, Hossein G, Motamed F, Farahmand F, Khodadad A, Ghajarzadeh M, Rezaei N, Mehrabani S. Comparison of one and two-day bowel preparation with polyethylene glycol in pediatric colonscopy. Turk J Gastroenterol 2015; 26: 232-5.
- 16. Sorser S, Konanki V, Hursh A, Hagglund K and Lyons H. 1-day bowel preparation with polyethylene glycol 3350 is as effective and safe as a 3-day preparation for colonscopy in children. BMC Research Notes, 7:648, 2014.
- Elitsur R, Butcher L, Vicki L, Elitsur Y. Polyethylene glycol 3350 based colon cleaning protocol: 2 d vs 4 d head to head comparison. World J Gastrointest Endosc (2013) 16; (4): 165-168.
- El-Baba M.F, Padilla M, Houston C, Madani S, Lin CH, Thomas R, Toila V. A prospective study comparing oral sodium phosphate solution to a bowel cleansing preparation with nutrition food package in children. J Pediatr Gastroenterol Nutr 2006; 42:174–177
- 19. US Food and Drug administration (FDA). FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM381084.pdf 2014.



Study	Year	No	Age	Regimen 1	Regimen 2	Regimen 3	Regimen 4	Context	Randomisation	Allocation Concealment	Blinding	Incomplete Outcomes	Selective reporting	Other
Gremse et al	1996	34	3 years - 17 years	Sodium Phosphate	PEG	N/A	N/A	Elective Colonoscopy	Unclear - one of the authors randomised patients into groups	One of the authors assigned the patients to their groups, also perform colonoscopies	Appear Single Blind	Unclear, no ITT	High – Details of adverse events not given	None
Sinha et al	2007	126	Mean 3 years	Sodium Chloride	PEG	Ringer Lactate	N/A	Elective surgery	Unclear	Unclear	Appear Single Blind	Low risk	Unclear risk	None
Kierkus et al	2013	240	10 years – 18 years	BPEG	PEG	Sennosides	N/A	Elective colonoscopy	List Created by independent person using block	Yes	Single Blind	Low risk	Low Risk	None
El-Baba et al	2006	62	4 years – 18 years	Pre-packaged food kit, magnesium citrate	Sodium Phosphate	N/A	N/A	Elective colonoscopy	Computer random number generator	Unclear	Single Blind	Unclear	Low risk	None apparent
Turner et al	2009	83	4 years – 18 years	Pico-Salax	PEG-ELS	N/A	N/A	Elective colonoscopy	Computer- generated list in blocks of 6	Yes	Single Blind	Yes	Low risk	Funded by pharma but not involved in study
Trautwein et al	1996	140	5 years – 18 years	X-Pep and Sodium Phosphate	Magnesium citrate and Sodium phosphate	N/A	N/A	Elective colonoscopy	Unclear	Unclear	Unclear	Unclear	Unclear Risk	None apparent
Kumar et al	2013	30	1 month – 7 years	Normal Saline	PEG	N/A	N/A	Various surgical procedures	Unclear	Unclear	Unclear	Low risk	Low	None apparent
Pinfield et al	1999	63	18 months - 16 years	Picolax	Bisacodyl + Phosphate enema	N/A	N/A	Elective colonoscopy	Unclear	Sealed envelopes	Single blind	High Risk – only adverse events	High risk	None apparent
Di Nardo et al	2014	299	2 years – 18 years	PEG-ELS with simethicone	PEG with citrate and bisacodyl	PEG 3350 with ascorbic acid	Sodium picosulphate, Magesium oxide and citric acid	Elective colonoscopy	Computer generated list	Opaque sealed signed envelop	Unblind	Low Risk	Low risk	None apparent
Elitsur et al	2013	93	Mean 10yrs	4-day protocol PEG 3350	2-day protocol PEG 3350 + bisacodyl	N/A	N/A	Elective Colonoscopy	Computer generated random list	unclear	unclear	unclear	High risk	None apparent


https://mc.manuscriptcentral.com/bmjpo


bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.

Sorser et al	2014	32	2 years – 21 years	3 day PEG 3350 Max 255g	3 day PEG 3350 max 85g/day	N/A	N/A	Elective Colonoscopy	No detail given	unclear	Single blind	Low risk	Low risk	None apparent
Najafi et al	2015	100	2 years – 14 years	1-day 2g/kg PEG + Bisacodyl Suppository	2-day 1.5g/kg PEG + Bisacodyl suppository	N/A	N/A	Elective Colonoscopy	Computer generated random numbers	A technician randomly assign	Single blind	Low Risk	Low Risk	None apparent
Dahsan et al	1999	70	3 years – 20 years	Magnesium citrate with X-prep	Dulcolax and Fleet Enema	Golytely (PEG)	N/A	Elective Colonoscopy	No detail given	unclear	Single blind	Low Risk	Low risk	None apparent
Terry et al	2013	33	6 years – 21 years	PEG-P	Senna	N/A	N/A	Elective Colonoscopy	Randomly chosen preparation packet	A nurse administer – no further details	Single Blind	Low risk	Low Risk	None apparent
Da Silva et al	1997	30	3 years – 14 years	Sodium Phosphate	PEG	N/A	N/A	Elective Colonoscopy	Computer generated randomly assigned	Unclear Risk	Unclear Risk	Unclear	High Risk	None apparent
PEG PEG	: Polye -ELS Po	thyle blyeth		oisacodyl I –electrolyte lava I without electroly	-	ı								
PEG	- P PO	iyeth	yiene giycol	i without electroin	les				Per					

https://mc.manuscriptcentral.com/bmjpo

bmjpo: first published as 10.1136/bmjpo-2017-000188 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.





https://mc.manuscriptcentral.com/bmjpo

	Senn	a	PEC	6		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Dahshan 1999	20	20	31	31	35.5%	1.00 [0.92, 1.08]	•
Kierkus 2013	25	80	35	80	33.1%	0.71 [0.47, 1.08]	-=-
Terry 2013	7	14	15	16	31.4%	0.53 [0.31, 0.91]	
Total (95% CI)		114		127	100.0%	0.73 [0.31, 1.76]	-
Total events	52		81				
Heterogeneity: Tau ² = Test for overall effect:				(P < 0.	00001); P	²= 95%	0.01 0.1 1 10 100 Favours [PEG] Favours [Senna]



04.00/ 4.00/0.00 4.401	M-H, Random, 95% Cl
81.8% 1.00 [0.89, 1.13] 18.2% 0.96 [0.75, 1.24] 100.0% 0.99 [0.89, 1.11] ; I ² = 0%	0.01 0.1 10 Favours [Sodium Pico] Favours [PEG-ELS]
5x41mm (96 x 96	DPI)
	100.0% 0.99 [0.89, 1.11] ; I ^p = 0%

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.

	Sodium		PEG EL		Materia	Risk Ratio		Ratio	
Study or Subgroup Di Nardo 2014	Events 1	Total 75	Events 15	Total 74		M-H, Random, 95% Cl 0.07 [0.01, 0.49]		om, 95% Cl	
Turner 2009	1	46	30	43					
Total (95% CI)		121		117	100.0%	0.04 [0.01, 0.18]	-		
Total events Heterogeneity: Tau² =	2 = 0.00: Chi ²	= 0.28	45 df=1 (P:	= 0.60	0: I ² = 0%		t at	L	
Test for overall effect:	Z = 4.36 (F	P < 0.000	01)		,,		0.01 0.1 Favours [Sodium Pico]	1 10 Favours [PEG-ELS]	100
				21	15x43	mm (96 x 96	DPI)		

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.



Sinha 2007 37 40 53 55 75.8% 0.96 [0.87, 1.06] Total (95% Cl) 55 70 100.0% 0.95 [0.87, 1.04] Total events 51 68 Heterogeneity: Tau ² = 0.00; Chi ² = 0.06, df = 1 (P = 0.81); l ² = 0% 0.7 0.85 1 1.2 1.5	Study or Subgroup			Risk Ratio M-H, Random, 95% Cl	Risk Ratio M-H, Random, 95% Cl
Total events 51 68 Heterogeneity: Tau [*] = 0.00; Chi [*] = 0.06; df=1 (P=0.81); P=0% Testfor overall effect Z=1.04 (P=0.30) 210x40mm (96 x 96 DPI)	Kumar 2013 Sinha 2007	14 15 37 40	15 15 24.2% 53 55 75.8%	0.94 [0.78, 1.12] 0.96 [0.87, 1.06]	-
Testfor overall effect Z = 1.04 (P = 0.30) 210x40mm (96 x 96 DPI)	Total events	51	68	0.95 [0.87, 1.04]	
	Heterogeneity: Tau² = 0 Test for overall effect: Z	.00; Chi ² = 0.06, df = = 1.04 (P = 0.30)	1 (P = 0.81); I ² = 0%		0.7 0.85 1 1.2 1.5 Favours [PEG] Favours [Normal saline]
			210×40m		
			21084011	IIII (90 X 90 DPI)	

https://mc.manuscriptcentral.com/bmjpo

Study or Subarous	NaP		PEG		Moight	Risk Ratio	Risk Ratio
Study or Subgroup Da Silva 1997 Gremse 1996	10 18	10tal 15 19	Events 11 8	15		M-H, Random, 95% CI 0.91 [0.57, 1.45] 1.78 [1.09, 2.89]	
īotal (95% CI) īotal events Heterogeneity: Tau² = īest for overall effect	28 = 0.17; Chi : Z = 0.70 (34 2 = 3.81 P = 0.4	19 , df = 1 (1 8)		100.0% 5); I² = 74		0.1 0.2 0.5 1 2 5 10 Favours [NaP] Favours [PEG]
				201	.x41m	ım (96 x 96 DF	PI)

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

Appendix 1 - Search strategy

vid EMBASE 1974 to 16 July 2016

- 1. exp colonoscopy/ OR colonoscop*.mp.
- 2. Surgery OR procedure
- 3. 1 or 2
- 4. infant/
- 5. child/
- 6. school child/
- 7. adolescent/
- 8. (infant* or child* or pediatric* or paediatric* or adolescent* or neonat* or toddler or young).mp.
- 9. 4 or 5 or 6 or 7 or 8
- 10. colon lavage/
- 11. intestine preparation/
- 12. exp laxative/
- 13. exp macrogol derivative/
- 14. exp phosphate/
- 15. exp citric acid/
- 16. exp magnesium oxide/
- 17. exp bisacodyl/
- 18. exp organometallic compound/
- 19. exp sulfate/
- 20. exp anthraquinone derivative/
- 21. exp enema/

22. (cathartic* or polyethylene glycol* or laxative* or phosphate* or citrate* or magnesium oxide* or bisacodyl or organometallic compound* or sulfat* or anthraquinone* or enema or bowel preparation or bowel cleansing or PEG-ELS or macrogol* or senna or docusate sodium or Sodium picosulphate or Cascara or casanthranol or Buckthorn or senokot or Aloe Vera or aloin Phenolphthalein or Dulcolax or stimulant or osmotic).mp.


23. (Miralax or Transipeg or Movicol or Forlax or Idrolax or GoLytely or PMF-100 or Golitely or Nulitely or Fortans or TriLyte or Colyte or lactulose or disaccharide or Apo-Lactulose or Chronulac or lactitol or sorbitol or Generlac or Cephulac or Cholac or Constilac or Enulose or Cilac or Heptalac or Actilax or Duphalac or Kristalose or Citroma or Osmoprep or Visicol).mp.

24. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23

- 25. 3 and 9 and 24
- 26. CROSSOVER PROCEDURE.sh.
- 27. DOUBLE-BLIND PROCEDURE.sh.
- 28. SINGLE-BLIND PROCEDURE.sh.
- 29. (crossover* or cross over*).ti,ab.
- 30. placebo*.ti,ab.
- 31. (doubl* adj blind*).ti,ab.
- 32. allocat*.ti,ab.
- 33. trial.ti.
- 34. RANDOMIZED CONTROLLED TRIAL.sh.
- 35. random*.ti,ab.
- 36. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
- 37. (exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not (exp human/ or human
- cell/ or (human or humans or man or men or wom?n).ti.)



38. 36 not 37



Bowel preparation for elective procedures in Children: A Systematic Review and meta-analysis

Journal:	BMJ Paediatrics Open
Manuscript ID	bmjpo-2017-000118.R1
Article Type:	Original article
Date Submitted by the Author:	14-Jul-2017
Complete List of Authors:	Gordon, Morris; University of Central Lancashire, Karlsen, Fiona; Blackpool Victoria Hospital Isaji, Sahira; Blackpool Victoria Hospital Ong, Teck Guan; Blackpool Victoria Hospital
Keywords:	Evidence Based Medicine, Gastroenterology



Bowel preparation for elective procedures in Children: A Systematic Review and meta-analysis

Morris Gordon (1,2), Fiona Karlsen (2), Sahira Isaji (2), Guan-ong Teck (2)

- 1. School of Medicine and Dentistry, University of Central Lancashire, Preston UK
- 2. Department of Paediatrics, Blackpool Victoria Hospital, Blackpool, UK

Contact information :

Dr Morris Gordon

HA118 Harrington building

University of Central Lancashire

Preston

UK

Email: mgordon@uclan.ac.uk

Phone ++44 1253 300000

Word count: 2526

Keywords: Bowel preparation, Bowel clearance, colonoscopy, systematic review

Funding: None

What is known about the subject

- Bowel preparation is vital to imaging and surgery in young people, but it is key to consider tolerability as well as efficacy in these patients
- Previous systematic reviews have only considered preparation for imaging and limit the age range, despite paediatricians often caring for children till older.

What this study adds

- Despite many trials, there is much clinical heterogeneity and risk of bias concerns with the evidence base, as well as poor safety and tolerability reporting.
- There is evidence that PEG regimens are effective. However, when compared, sodium picosulphate was better tolerated than PEG
- Future research needs to address these key methodology issues and also consider safety and tolerability, as well as efficacy.

Abstract

Objective: Adequate bowel preparation is crucial for both surgery and imaging in young people. Whilst systematic reviews have considered preparation for colonoscopy, they do not consider surgical interventions and to the age of 16, despite it being normal practice for paediatric gastroenterologists to care for transitioning children till older. We carried out a systematic review investigating the optimum bowel preparation agents for all indications in children and young people.

Design: A Cochrane format systematic review of randomised controlled trials (RCTs). Data extraction and assessment of methodological quality were performed independently by two reviewers. Methodological quality was assessed using the Cochrane risk of bias tool.

Patients: Young people requiring bowel preparation for any elective procedure, as defined by the primary studies.

Interventions: RCTs comparing bowel preparation with placebo or other interventions.

Main outcome measures: Adequacy of bowel preparation, tolerability and adverse events.

Results: The search yielded 2124 results and 15 randomised controlled studies (n = 1435), but heterogeneity limited synthesis. Meta-analysis of 2 studies comparing PEG with sodium phosphate showed no difference in the quality of bowel preparation (RR 1.27 [95% CI, 0.66-2.44]). Two studies comparing sodium picosulphate / magnesium citrate with PEG found no difference in bowel preparation, but significantly higher number of patients needing nasogastric tube insertion in the PEG-ELS (RR 0.04 [95% CI, 0.01-0.18]). Meta-analysis of 3 studies (n = 241) found no difference between PEG and Sennasoids (RR 0.73 [95% CI, 0.31-1.71]).

Conclusions: The evidence base is clinically heterogeneous and methodologically at risk of bias. There is evidence that all regimens are equally effective. However, sodium picosulphate was better tolerated than PEG. Future research is needed with all agents and should seek to consider safety and tolerability, as well as efficacy.

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

Background:

Bowel imaging is a crucial modality in the diagnosis and monitoring of Inflammatory Bowel Disease (IBD), as well as surgery frequently being required in such patients. Multiple studies have suggested that bowel preparations must be individually tailored according to patient age, size and clinical status.¹ However, currently there is no internationally recognised gold standard regimen for paediatric bowel preparations.² Several regimens have been tried with the aim of identifying the safest, efficacious and tolerable combination, with varying success.³

Bowel preparation regimens can be based on lavage (bowel clean out) or cathartics (agents that accelerates defecation). Examples included; large volume of polyethylene glycol-electrolyte (PEG-ELS) lavage solution, sodium phosphate (an oral, low-volume, hyperosmotic agent), sodium pico-sulphate, bisacodyl and dietary measures, such as diet packs or clear liquid diets (often in combination with other agents).

Adequate bowel preparation prior to such procedures is crucial to ensure complete visualisation of the colonic mucosa (thus successful diagnostic and therapeutic colonoscopy, endoscopy and capsule endoscopy) and to minimize the risk of possible contamination during surgery. Administration of the agents is much more problematic in children compared to adults who manage to take the agents readily. In un-cooperative children, use of a naso-gastric tube to administer the agents has been reported to be an effective method to guarantee bowel wash out.⁴ Reduced tolerance can result in poor outcomes due to inadequate preparation, increased rate of complications, extended procedural time and missed lesions.³ Additionally, side effects have previously been noted, such as hyperphosphataemia in children who receive sodium phosphate.⁴

Whilst previous reviews have considered preparation for colonoscopy³, they do not always consider surgical interventions and often limit their populations at the age of 16, despite it being normal practice for paediatric gastroenterologists to look after such patients for a number of years before transition to adult services.⁵

We carried out an up to date systematic review using the Cochrane collaboration format to summarise the available evidence investigating the optimum bowel preparation agents for all indications in children and young people.

Methods:

The objectives of this review were to evaluate the efficacy and safety of different bowel preparation for young people for any indication. A full protocol for the study was completed by the authors prior to commencement of the study and is available on request. This set out the procedure for the search, study screening, data extraction, risk of bias evaluation and analysis.

Criteria for considering studies for this review

RCTs were included in this systematic review. Participants were aged 0 to 21 years. This age range was selected after a scoping search and discussion with local stakeholders (tertiary centres) confirmed that it can be normal practice in pediatric gastroenterology for these patient groups to have variable transition to adult services, but 21 years was agreed as an absolute cut off and reflected several studies that would otherwise be excluded. Studies with adults included that did not allow analysis of this Paediatric age range were excluded. Studies compared bowel preparation with another bowel preparation or placebo, with all forms and dosing regimens considered. The purpose of bowel clearance was for colonoscopy or elective surgery. Studies were excluded if the purpose was to treat faecal impaction or encopresis. The primary outcome measure for the studies was the number of adequate bowel preparations, as defined by the included studies. Secondary outcomes included: tolerability (the propoprtion of children who could take the given therapy without the need for support through a nasogastric tube or incomplete dosing), Duration of procedure, Missed lesions due to inadequate bowel preparation and occurrence of any adverse events.

Search methods for identification of studies

Electronic searches (search strategy not limited by language) were completed of MEDLINE, The Cochrane Central Register of Controlled Trials, EMBASE and CINAHL (Inception- 15 July 2016), Appendix 1. References of included trials were also searched. Manufacturers were contacted to identify further negative and unpublished research. Abstracts were considered for inclusion if full details to judge inclusion were offered or available from the authors after contact by the study team.

Data extraction and assessment of methodological quality of included studies were independently performed by 2 authors and disagreements solved with involvement of the third author.

Data collection and analysis

All identified abstracts and results from searches were reviewed by the authors. If the reference appeared relevant, a full copy of the study was obtained. After reading the full texts, each author independently assessed the eligibility of all trials identified based on the inclusion criteria above. Disagreement among authors was discussed and agreement reached by consensus. If the data to judge inclusion were unclear, attempts were made to contact the authors.

A data extraction form was developed and piloted to extract information on relevant features and results of all primary and secondary outcomes of included studies. The two reviewers separately extracted and recorded data on the predefined checklist, with disagreement discussed and consensus reached.

The risk of bias of selected trials was assessed independently by the authors using the Cochrane risk of bias tool with disagreement once again resolved by reaching consensus. Study authors were contacted for further information when insufficient information was offered to judge risk of bias or data were missing for primary outcomes. Analysis was completed using Revman (Review Manager 5.2, V.5.2.9, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2012).

The primary outcome—efficacy of bowel preparation agents—was assessed using the Risk Ratio (RR) with 95% CI. The secondary outcomes were assessed by calculating the risk ratio (RR) and 95% CI or the MD with 95% CI, as indicated. The authors of included studies were again contacted to supply any missing data. Heterogeneity among trial results was assessed by inspection of graphical presentations and by calculating the χ^2 test of heterogeneity (a p value of 0.10 was regarded as statistically significant). We also used the I2 statistic to quantity the effect of heterogeneity.¹² A result of less than 25% was defined as low, upto 75% moderate and above 75% high heterogeneity. A random-effects model was used, with a sensitivity analysis with the fixed-effects model, to identify differences in results that would suggest heterogeneity.

Results:

The electronic database search identified 2124 studies that were screened for inclusion. Of these, 15 studies (n = 1435) were judged to be potentially relevant and subjected to full text review (Figure 1). Only 12 papers needed consideration of a third author (less than 1%) to reach consensus, with one included and 11 excluded. Experts were contacted, but no extra reports were received and no further studies were identified from drug companies.

Description of studies

Excluded studies

Nine reports were excluded for failing to meet the inclusion criteria. Five were not solely with patients under 21 years of age, three were not RCTs and one was an abstract with insufficient data to judge inclusion.

Included studies

The 15 RCTs included described various regimens and comparative agents (Table 1). Four studies compared various different regimens and combinations of PEG, Two compared polyethylene glycol (PEG) with oral sodium phosphate, two compared PEG with Normal Saline, three compared multiple combinations of PEG, sennasoids and sodium picosluphate, two diet kits with sodium phosphate, one study compared sodium picosulphate with phosphate enemas and one sodium picospulphate with PEG.



Page	8	of	26
------	---	----	----

Study	Year	No	Age	Regimen 1	Regimen 2	Regimen 3	Regimen 4	Context	Randomisation	Allocation Concealment	Blinding	Incomplete Outcomes	Selective reporting	Other
Gremse et al	1996	34	3 years - 17 years	Sodium Phosphate	PEG	N/A	N/A	Elective Colonoscopy	Unclear - one of the authors randomised patients into groups	One of the authors assigned the patients to their groups, also perform colonoscopies	Appear Single Blind	Unclear, no ITT	High – Details of adverse events not given	None
Sinha et al	2007	126	Mean 3 years	Sodium Chloride	PEG	Ringer Lactate	N/A	Elective surgery	Unclear	Unclear	Appear Single Blind	Low risk	Unclear risk	None
Kierkus et al	2013	240	10 years – 18 years	BPEG	PEG	Sennosides	N/A	Elective colonoscopy	List Created by independent person using block	Yes	Single Blind	Low risk	Low Risk	None
El-Baba et al	2006	62	4 years – 18 years	Pre-packaged food kit, magnesium citrate	Sodium Phosphate	N/A	N/A	Elective colonoscopy	Computer random number generator	Unclear	Single Blind	Unclear	Low risk	None apparent
Turner et al	2009	83	4 years – 18 years	Pico-Salax	PEG-ELS	N/A	N/A	Elective colonoscopy	Computer- generated list in blocks of 6	Yes	Single Blind	Yes	Low risk	Funded by pharma but not involved in study
Trautwein et al	1996	140	5 years – 18 years	X-Pep and Sodium Phosphate	Magnesium citrate and Sodium phosphate	N/A	N/A	Elective colonoscopy	Unclear	Unclear	Unclear	Unclear	Unclear Risk	None apparent
Kumar et al	2013	30	1 month – 7 years	Normal Saline	PEG	N/A	N/A	Various surgical procedures	Unclear	Unclear	Unclear	Low risk	Low	None apparent
Pinfield et al	1999	63	18 months - 16 years	Picolax	Bisacodyl + Phosphate enema	N/A	N/A	Elective colonoscopy	Unclear	Sealed envelopes	Single blind	High Risk – only adverse events	High risk	None apparent
Di Nardo et al	2014	299	2 years – 18 years	PEG-ELS with simethicone	PEG with citrate and bisacodyl	PEG 3350 with ascorbic acid	Sodium picosulphate, Magesium oxide and citric acid	Elective colonoscopy	Computer generated list	Opaque sealed signed envelop	Unblind	Low Risk	Low risk	None apparent
Elitsur et al	2013	93	Mean 10yrs	4-day protocol PEG 3350	2-day protocol PEG 3350 + bisacodyl	N/A	N/A	Elective Colonoscopy	Computer generated random list	unclear	unclear	unclear	High risk	None apparent

https://mc.manuscriptcentral.com/bmjpo

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.

Page	9 (of	26
------	-----	----	----

Elective

Colonoscopy

No detail given

3 day PEG 3350 max

N/A

N/A

6113350Max 255g3350Max 255g3350Max 255g3350Max 255g3350Max 257g2-day1.5g/kgPEG +Bisacody1.5g/kgSuppositoryBisacodysuppositoryBisacodysuppositoryBisacodysuppositoryDucloaxand Flee13Dahsan et1999703 years - 20Wagnesium citrateDulcolaxDulcolaxand Flee </th <th>4 5</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	4 5						
673350336033703370337033703370 <td>5</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	5						
7 Max 255g 85g/day 9 Najafi et al 2015 100 2 years - 14 1-day 2g/kg PEG + 2-day 10 11 1 1 1-day 2g/kg PEG + Bisacodyl Suppository 12 Dahsan et 1999 70 3 years - 20 Magnesium citrate Dulcolax 14 al 1 9 70 3 years - 21 PEG - Dulcolax 16 Terry et al 2013 33 6 years - 21 PEG -P Senna 19 Da Silva et 1997 30 3 years - 14 Sodium Phosphate PEG 20 Da Silva et 1997 30 3 years - 14 Years Sodium Phosphate PEG 21 al 1997 30 3 years - 14 Sodium Phosphate PEG 22 Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes) 23 33 34 35 36 37	6	Sorser et al	2014	32		,	3 day PE
8 Najafi et al 2015 100 2 years - 14 years 1-day 2g/kg PEG + Bisacodyl Suppository 2-day 1.5g/kg PEG + Bisacodyl supposit 11 11 11 11 1.5g/kg PEG + Bisacodyl suppository 2-day 1.5g/kg 1.5g/kg 12 Dahsan et al 1999 70 3 years - 20 years Magnesium citrate with X-prep Dulcolax and Flee Fnema 16 Terry et al 2013 33 6 years - 21 years PEG-P Senna 19 Da Silva et al 1997 30 3 years - 14 years Sodium Phosphate PEG 20 Da Silva et al 1997 30 3 years - 14 years Sodium Phosphate PEG 21 al 1997 30 3 years - 14 years Sodium Phosphate PEG 23 Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes) 33 34 33 34 35 36 37 33	7				years		85g/day
9 10 11 11 12Najafi et al 20152015100 1002 years1-day 2g/kg PEG + Bisacodyl Suppository2-day 1.5g/kg PEG + Bisacodyl supposit13 14 13 14 14Dahsan et al199970 703 years - 20 yearsMagnesium citrate with X-prepDulcolax and Flee Enema16 17 18 19Terry et al al201333 336 years - 21 yearsPEG-PSenna PEG18 19 20 20 21 21 22Da Silva et al199730 30 3 years - 14 yearsSodium Phosphate peG -PPEG24 23 24Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes)PEG26 27 28 29 3031 32 3334 35 36 36 3737							
10 11 Suppository PEG + 11 Dahsan et 1999 70 3 years - 20 Magnesium citrate Dulcolax 14 al 1999 70 3 years - 20 with X-prep and Flee 15 Terry et al 2013 33 6 years - 21 PEG-P Senna 16 Terry et al 2013 33 6 years - 21 PEG-P Senna 18 19 1 30 3 years - 14 Sodium Phosphate PEG 20 Da Silva et 1997 30 3 years - 14 Sodium Phosphate PEG 21 al 1997 30 3 years - 14 Sodium Phosphate PEG 23 Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes) 30 31 32 33 34 35 36 37		Najafi et al	2015	100			-
11 Image: Second Structure Bisacody supposite 13 Dahsan et 1999 70 3 years - 20 Magnesium citrate Dulcolax and Flee 14 al 1999 70 3 years - 21 PEG-P Senna 16 Terry et al 2013 33 6 years - 21 PEG-P Senna 18 Image: Second	10				years		
13 14 alDahsan et al1999 199970 20 years3 years - 20 yearsMagnesium citrate with X-prepDulcolax and Flee Enema16 17 18 19Terry et al 2013201333 336 years - 21 yearsPEG-PSenna20 20<							Bisacody
13 al years with X-prep and Flee 14 al 2013 33 6 years - 21 PEG-P Senna 16 Terry et al 2013 33 6 years - 21 PEG-P Senna 18 19 20 Da Silva et 1997 30 3 years - 14 Sodium Phosphate PEG 20 Da Silva et 1997 30 3 years - 14 Sodium Phosphate PEG 21 al 1997 30 3 years - 14 Sodium Phosphate PEG 23 Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes) 26 glycol without electrolytes) 31 33 34 35 36 37 37 37 37 37 37 30 33		Debaarat	1000	70	2 years - 20	Magnosium citrato	supposite
14 al Control Enema 15 16 Terry et al 2013 33 6 years - 21 years PEG-P Senna 18 19 Da Silva et 1997 30 3 years - 14 years Sodium Phosphate PEG 20 Da Silva et 1997 30 3 years - 14 years Sodium Phosphate PEG 21 al 1 1997 30 3 years - 14 years Sodium Phosphate PEG 23 Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes) glycol without electrolytes) 27 28 29 30 31 33 34 33 34 35 36 37 37 37			1999	70	-		and Fleet
16 17 18Terry et al2013336 years - 21 yearsPEG-PSenna20 20 20 20 21 alDa Silva et al1997303 years - 14 yearsSodium PhosphatePEG21 22 23Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes)Sodium PhosphatePEG26 29 30 31 31 32 33 34 35 36 37Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes)		aı			,		
17Terry et al2013336 years - 21PEG-PSellina19Da Silva et al1997303 years - 14 yearsSodium PhosphatePEG21alTable 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes)PEG: Poly ears28303131323334353637							
18 Image: second se		Terry et al	2013	33	-	PEG-P	Senna
19 Da Silva et al 1997 30 3 years - 14 years Sodium Phosphate PEG 21 al 1 1997 30 3 years - 14 years Sodium Phosphate PEG 23 Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes) glycol without electrolytes) 26 glycol without electrolytes) 30 31 32 33 34 35 36 37					years		
20 21 alDa Silva et al199730 303 years - 14 yearsSodium PhosphatePEG22 23Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes)PEG26 27 28 29 30 31 31 32 33 34 35 36 37Table 1. Characteristics of included studies and (BPEG: PEG combined with bisacodyl; PEG: Poly estate and the studies and estate and the studies and (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes)							
21 al 22 Table 1. Characteristics of included studies and 25 (BPEG: PEG combined with bisacodyl; PEG: Poly 26 glycol without electrolytes) 27 28 29 30 31 32 33 34 35 36 37 37		Da Silva et	1997	30	3 years – 14	Sodium Phosphate	PEG
23 Table 1. Characteristics of included studies and 25 (BPEG: PEG combined with bisacodyl; PEG: Poly 26 glycol without electrolytes) 27 28 29 30 31 32 33 34 35 36 37 37	21	al			years		
24 Table 1. Characteristics of included studies and25(BPEG: PEG combined with bisacodyl; PEG: Poly26glycol without electrolytes)272829303132333435363737							
 (BPEG: PEG combined with bisacodyl; PEG: Poly glycol without electrolytes) glycol without electrolytes) 30 31 32 33 34 35 36 37 		Tab		 	et a riation a	finaludad atudi	
26 glycol without electrolytes) 27 28 29 30 31 32 33 34 35 36 37							
27 28 29 30 31 32 33 34 35 36 37		•					3: POIVe
28 29 30 31 32 33 34 35 36 37		glyc	ol wit	hout	electrolyte	es)	
29 30 31 32 33 34 35 36 37							
30 31 32 33 34 35 36 37							
32 33 34 35 36 37							
33 34 35 36 37	31						
34 35 36 37							
35 36 37							
36 37	- 34						
37							
	35						
	35 36						
	35 36 37						
40	35 36 37 38						
41	35 36 37 38 39						
42	35 36 37 38 39 40						
	35 36 37 38 39 40 41 42						
	35 36 37 38 39 40 41 42 43						
	35 36 37 38 39 40 41 42 43 44						
	35 36 37 38 39 40 41 42 43 44 45						
48 April 26, 2024 by guest. Protected by copyright.	35 36 37 38 39 40 41 42 43 44 45 46						
48 theirvage vid heteoter B troup vid NS05. AS lind (ap vage imd (35 36 37 38 39 40 41 42 43 44 45 46 47	, τοργήθης.	(g paio)	9 10 - J	.1Sອກຽ √ດ +z	טון אסי צט.	oo.(ma.n

2-day 1.5g/kg PEG + Bisacodyl suppository	N/A	N/A	Elective Colonoscopy	Computer generated random numbers	A technician randomly assign	Single blind	Low Risk	Low Risk	None apparent
Dulcolax and Fleet Enema	Golytely (PEG)	N/A	Elective Colonoscopy	No detail given	unclear	Single blind	Low Risk	Low risk	None apparent
Senna	N/A	N/A	Elective Colonoscopy	Randomly chosen preparation packet	A nurse administer – no further details	Single Blind	Low risk	Low Risk	None apparent
PEG	N/A 🔷	N/A	Elective Colonoscopy	Computer generated randomly assigned	Unclear Risk	Unclear Risk	Unclear	High Risk	None apparent
a. i oiyetii			, or oryening	ene glycol –ele				i i oiyetii	yene

unclear

Single

blind

Low risk

Low risk

None apparent

https://mc.manuscriptcentral.com/bmjpo

no /mop.imd.naqosbasqimd/\.qtth mort babsolnwod .7102 nadmatqa2 81 no 811000-7102-oqimd\3611.01 as badsiduq terit :oqimd

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

Seven studies were rated as low risk for random sequence generation (selection bias) because these studies employed computer-generated randomisation. The remaining studies described themselves as randomised but, with no further details given or available from authors, were rated as unclear risk of bias.

Five studies were rated as low risk of bias for allocation concealment (selection bias). Nine remaining studies were rated as unclear risk of bias for allocation concealment as the methods were not clearly described in the manuscripts. One described the allocated researcher as performing colonoscopies and was rated as high risk.

Ten studies were blinded and were judged to be at low risk of bias for blinding of personnel (performance bias) for such an intervention. Four studies described themselves as blinded, but gave no further details so was rated as unclear risk of bias. One study was open-label and judged to be at high risk of bias for blinding.

Eight studies reported full and appropriate data and satisfactorily documented withdrawals and dropouts and were therefore judged to be at low risk of bias for incomplete outcome data (attrition bias) and nine were judged as low risk for selective reporting (reporting bias). Two studies did not record full data for all patients and were judged high risk of bias for attrition bias. Four studies did not offer outcome data regarding side effects and tolerability so were judged at high risk for reporting bias.

All studies were judged to be at low risk for other sources of bias. However, the small sample sized of many of these studies is concerning, suggesting they were pilot or similarly underpowered studies, raising a further concern regarding bias. Details are summarised in Table 1.

The 15 studies present significant clinical and methodological heterogeneity (Table 1) and this severely limits the scope for synthesis.

PEG vs Sennasoids

Meta-analysis of 3 studies (n = 241)^{6,7,8} found no difference between polyethylene glycol (PEG) and Sennasoids in adequate bowel preparation (RR 0.73 [95% CI, 0.31-1.76], Figure 2). High statistical heterogeneity was noted. Data regarding tolerability and safety was not presented to allow synthesis.

Sodium picosulphate and magnesium citrate versus polyethylene glycol-electrolyte lavage solution (PEG-ELS)

Within these two studies versus PEG-ELS^{9,10}, equivocal adequacy of bowel preparation was seen (RR 0.99 [95% CI, 0.89-1.11], Figure 3). PEG's acceptability was reportedly poorer than sodium picosulphate in both studies. Meta-analysis of two PEG-ELS studies using the random effects model found a significantly higher number of patients needing nasogastric tube insertion in the PEG-ELS group (45 of 117) than the sodium picosulphate group (2 of 121), (RR 0.04 [95% CI, 0.01-0.18], Figure 4).

One patient in the PEG-ELS group and one in the sodium picosulphate group in the two studies were assessed as dehydrated and required intravenous (IV) fluids. For the PEG-ELS patient, a 10-year-old girl is reported who required intravenous fluid for 6 hours because of lethargy and dehydration (dryness of the oral mucosa and orthostatic hypotension) with serum electrolyte and glucose serum levels within the normal range. For the child in the sodium picosulphate group, a 12-year-old girl is reported that required intravenous fluids for 2 hours due to mild lethargy post procedure and was discharged well thereafter. Her vital signs were always within normal limits, but her serum osmolality was 316 mosm/L; she had drunk only two glasses of apple juice during the entire duration of the bowel cleanout. No other serious adverse events were noted.

PEG vs Normal Saline

Meta-analysis of 2 studies (n = 125) comparing PEG with normal saline^{11,12} found no difference in rate of adequate bowel preparation (RR 0.95 [95% CI, 0.87-1.04], Figure 5). Adverse events were not reported homogenously to allow analysis, but occurred in both groups, including abdominal pain and vomiting.

PEG vs Sodium phosphate

There were two studies concerning 63 participants.^{4,13} Meta-analysis of 2 studies using the randomeffect model found no difference in the adequacy of bowel preparation (RR 1.27 [95% CI, 0.66-2.45], Figure 6). Again, high statistical heterogeneity was noted. One of the studies needed to insert a nasogastric tube in all patients receiving PEG, while in the remaining study, 53% of participants in the PEG group were unable to finish taking the solution whilst all the patients in the sodium phosphate group could complete the medication. As these were reported differently, no meta-analysis was performed. No serious adverse events were reported.

Other studies

Within the remaining studies^{1, 14-18} no meta-analysis was possible. However, no individual study found any different in adequacy of bowel preparation or adverse events. Tolerability was not well reported across studies. Whilst secondary outcome analysis for further items were planned, data was not presented to allow this to take place.

Discussion:

Despite the common requirement for bowel preparation in young people, the results of this review have highlighted a very poor evidence base. A mixture of clinical heterogeneity related to multiple agent regimens and methodological heterogeneity limiting the ability for meta-analysis has significantly limited synthesis. In multiple small analyses, PEG-ELS, Senna, Normal Saline, Sodium phosphate and Sodium picosulphate / Magnesium citrate found no difference in adequacy of bowel preparation. This was similar across the remaining individual studies. As such, despite the significant weaknesses of the evidence base, it is worth noting that no difference in adequacy of bowel preparation has been reported in any included study. This was also the case with adverse events, although it must be noted these were reported in an extremely heterogeneous fashion, with individual minor, major and patient overall recording of events across studies.

Of note, there was a significant difference in favour of sodium pico-sulphate and magnesium citrate regarding tolerability, specifically the need for a nasogastric tube to complete the bowel preparation. This is a particularly interesting finding, as the primary studies highlighted that whilst tolerability of PEG was extremely poor, smaller volumes than planned appeared to have little impact on efficacy. This raises the question of the need for the nasogastric tube at all and so this may need further investigation in the future. Sodium pico-sulphate was also compared to bisacodyl and a phosphate enema in a single study with equivocal preparation, tolerability and safety reported.

PEG appeared to be the least tolerable agent across all studies - with a number of the patients requiring a nasogastric tube insertion, but this is from qualitative synthesis of individual studies, with this outcome reported in heterogeneous fashion so meta-analysis was not possible. Additionally, as the age ranges of included participants varied greatly, it is hard to make firm conclusions on this finding as the need for nasogastric tubes is likely to be very age dependent. Oral sodium phosphate was well tolerated in individual studies. Despite the satisfactory tolerability and safety profile of sodium phosphate, it should be noted that care must be taken when using this agent as it can cause significant electrolyte imbalances. As such, it should not be used in patients with deranged baseline electrolytes, suboptimal renal and hepatic function, as it poses a risk of acute kidney injury and phosphate nephropathy.¹⁹

With all the agents studied the occurrence of minor adverse events such as abdominal pain, bloating, faecal incontinence, nausea, vomiting, headaches and anal irritation was comparable. No serious adverse events were reported in any of the studies. It should also be noted that in the context of elective surgery, there is growing recognition of the role for proceeding without bowel preparation.²⁰

The evidence base for this review covers a large number of trials with a reasonable number of patients, but is severely limited due to clinical and methodological heterogeneity, as well as concerns with risk of bias. As such, the findings of this review should be interpreted with extreme caution as it is difficult to draw firm conclusions for any of the investigated agents. it must also be noted that for the primary outcome, successful bowel preparation was 'as defined' by primary studies, with several different scoring systems and criteria used. This also limits the appropriateness of meta-analysis in this context, although those wishing to complete future studies should note the Ottawa scoring system²¹ was the only such scoring method reported in multiple studies. This is also true of adverse events, which were reported in a sporadic and inconsistent manner that prevented comment on even simple complaints, such as nausea or vomiting.

Considering the small sample sizes, the high degree of heterogeneity and a wide variation in the regimen of each cleansing agent; the findings of this review cannot be reliably used to inform clinical practise, but most usefully should inform future research. In particular, as the question of adequacy of bowel preparation has been established as essentially equivocal amongst all study agents, a shift of focus for future studies is needed. Given the unique needs of a paediatric population, considering the issue of tolerability as a primary outcome is vital and looking at the lower volume options presented as enteral agents could offer potential practical advantages and need a high quality study to investigate them.

Conclusions:

The publishing evidence base investigating this issue is large, but is clinically heterogeneous and at risk of bias. All regimens appear equivocal for adequacy of bowel preparation. However, when compared with sodium pico-sulphate, sodium pico-sulphate is better tolerated. Future research should seek to consider safety and tolerability, as well as efficacy, given the key importance of these issues in a childhood population.



Figure legend

Fig 1: Patient flow diagram

Fig 2: Forest plot for PEG vs Senna, adequacy of bowel preparation

Fig 3: Forest plot for Sodium picosulphate and magnesium citrate versus polyethylene glycolelectrolyte lavage solution (PEG-ELS), adequacy of bowel preparation

Fig 4: Forest plot for Sodium picosulphate and magnesium citrate versus polyethylene glycolelectrolyte lavage solution (PEG-ELS), Tolerability of agent

Fig 5: Forest plot for PEG vs Normal Saline, adequacy of bowel preparation

Fig 6: Forest plot for PEG vs Sodium Phosphate, adequacy of bowel preparation

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright


- 1. Trautwein AL, Vinitski LA, Peck SN. Bowel preparation before colonoscopy in the pediatric patient: A randomised study. *Gastroenterol Nurs* 1996;**19**:137–9.
- 2. Engum SA, Carter ME, Murphy D, Breckler FM, Schoonveld G, Grosfeld JL. Home bowel preparation for elective colonic procedures in children: Cost savings with quality assurance and improvement. J Pediatr Surg 2000;35:232-4.
- Pall H, Zacur GM, Kramer RE, et al. Bowel preparation for pediatric colonoscopy: report of the NASPGHAN endoscopy and procedures committee. J Pediatr Gastroenterol Nutr 2014;59:409-16.
- Gremse DA, Sacks AI, Raines S. Comparison of oral sodium phosphate to polyethylene glycol-based solution for bowel preparation for colonoscopy in children. J Ped Gastroenterol Nutr 1996;23:586-90.
- Hunter A, Mamula P. Bowel preparation for pediatric colonoscopy procedures. J Pediatr Gastroenterol Nutr. 2010;3:254-61.
- Terry NA, Chen-Lim ML, Ely E, Jatla M, Ciavardone D, Esch S, Farace L, Jannelli F, Puma A, Carlow D, Mamula P. Polyethylene Glycol Powder Solution Versus Senna for Bowel Preparation for Colonoscopy in Children. J Pediatr Gastroenterol Nutr 2013;56:215-9.
- Kierkus J, Horvath A, Szychta M, Woynarowski M, Wegner A, Wiernicka A, Dadalski M. High-versus Low-Volume Polyethylene Glycol Plus Laxatives versus Sennosides for Colonoscopy preparation in children. JPGN, Vol 57, 2. 2013.
- Dahshan A, Lin CH, Peters J, Thomas R, Tolia V. A Randomized, Prospective Study to Evaluate the Efficacy and Acceptance of Three Bowel Preparations for Colonscopy in Children. The American Journal of gastroenterology, (1999), 94.

BMJ Paediatrics Open

- Di-Nardo G, Aloi M, Cucchara S, Spada C, Hassan C, Civitelli F, Nuti F, Ziparo C, Pession A, Lima M, Torre G and Oliva S. Bowel Preparations for Colonoscopy: An RCT. American academy of paediatrics. 2014;10:1542
- Turner D, Benchimol E, Dunn H, Griffith A.M, Frost K, Scaini V, Avolio J, Ling SC. Pico-Salax versus polyethylene glycol for bowel cleanout before colonoscopy in children: a randomized controlled trial. Endoscopy 2009;41:1038-1045.
- 11. Kumar A, Hussain A. Preoperative bowel preparation in children: polyethylene glycol versus normal saline. African journal of paediatric surgery. 2013:10; 235-238.
- Sinha K, Kanojia RP, Rawat JD, Wakhlu A, Kureel SN, Tandon RK, Verma A. Comparison of three solutions for total gut irrigation in pediatric patients. Pediatr Surg Int. 2007;23:581-584.
- Da Silva MM, Briars GL, Patrick MK, Cleghorn GJ, Shepherd RW. Colonoscopy preparation in children: safety, efficacy and tolerance of high-versus low-volume cleansing methods. J Ped Gastroenterol Nutr. 1997;24:33-7.
- 14. Pinfield A, Stringer M. Randomised Trial of two pharmacological methods of bowel preparation for day case colonscopy. Arch Dis Child. 1999; 80:181-183.
- 15. Najafi M, Hossein G, Motamed F, Farahmand F, Khodadad A, Ghajarzadeh M, Rezaei N, Mehrabani S. Comparison of one and two-day bowel preparation with polyethylene glycol in pediatric colonscopy. Turk J Gastroenterol 2015; 26: 232-5.
- 16. Sorser S, Konanki V, Hursh A, Hagglund K and Lyons H. 1-day bowel preparation with polyethylene glycol 3350 is as effective and safe as a 3-day preparation for colonscopy in children. BMC Research Notes, 7:648, 2014.
- Elitsur R, Butcher L, Vicki L, Elitsur Y. Polyethylene glycol 3350 based colon cleaning protocol: 2 d vs 4 d head to head comparison. World J Gastrointest Endosc (2013) 16; (4): 165-168.
- El-Baba M.F, Padilla M, Houston C, Madani S, Lin CH, Thomas R, Toila V. A prospective study comparing oral sodium phosphate solution to a bowel cleansing preparation with nutrition food package in children. J Pediatr Gastroenterol Nutr 2006; 42:174–177

- 19. US Food and Drug administration (FDA). FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation.

<text><text>




bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.

-	
2	
3	
2 3 4 5 6 7 8 9 10	
7	
5	
6	
7	
~	
8	
9	
10	
10	
11	
12	
13	
10	
14	
15	
16	
10	
17	
18	
10	
13	
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 8 29 30 132 33 435 36 37 839	
21	
22	
22	
23	
24	
25	
20	
26	
27	
20	
20	
29	
30	
21	
51	
32	
33	
24	
34	
35	
36	
27	
31	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
49	
50	
51	
52	
52	
53	
54	
55	
00	
56	
57	
58	
20	
59	
~~	

60

1



64x14mm (300 x 300 DPI)

Study or Subgroup	Sodium Events		PEG E		Weight	Risk Ratio M-H, Random, 95% Cl	Risk Ratio M-H, Random, 95% Cl
Di Nardo 2014 Furner 2009	66 33	75 46	65 32	74 43	81.8%	1.00 [0.89, 1.13] 0.96 [0.75, 1.24]	
Fotal (95% CI) Fotal events Heterogeneity: Tau² = Fest for overall effect	99 = 0.00; Chi : Z = 0.09 (121 ² = 0.08, P = 0.92	97 df=1 (F !)		100.0% '); I ² = 0%		0.01 0.1 10 100 Favours (Sodium Pico) Favours (PEG-ELS)
				68	x13m	ım (300 x 300	DPI)

1	
2	
3 4 5 6 7	
4	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
$\begin{array}{c} 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 223\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39 \end{array}$	
22	
23	
24	
20	
20	
21	
20	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43 44	
44 45	
45 46	
40 47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59 60	
60	

60

1

Sodium Pico PEG ELS Risk Ratio Risk Ratio Di Nardo 2014 1 75 15 74 48.7% 0.07 [0.01, 0.49] Turner 2009 1 46 30 43 51.3% 0.03 [0.00, 0.22] Total (95% CI) 121 117 100.0% 0.04 [0.01, 0.18] Total (95% CI) 2 45 Heterogeneity: Tau ² = 0.00; Chi ² = 0.28, df = 1 (P = 0.60); P = 0% 0.01 0.1 1 10 Test for overall effect: Z = 4.36 (P < 0.0001) 68x13mm (300 x 300 DPI) 68x13mm (300 x 300 DPI) 68x13mm (300 x 300 DPI) 68x13mm (300 x 300 DPI)	100
Di Nardo 2014 1 75 15 74 48.7% 0.07 [0.01, 0.49] Turner 2009 1 46 30 43 51.3% 0.03 [0.00, 0.22] Total (95% Cl) 121 117 100.0% 0.04 [0.01, 0.18] Total events 2 45 Heterogeneity: Tau ² = 0.00; Chi ² = 0.28, df = 1 (P = 0.60); P = 0% Test for overall effect: Z = 4.36 (P < 0.0001) Favours [Sodium Pico] Favours [PEG-ELS]	100
Total (95% Cl) 121 117 100.0% 0.04 [0.01, 0.18] Total events 2 45 Heterogeneity: Tau ² = 0.00; Chi ² = 0.28, df = 1 (P = 0.60); i ² = 0% 0.01 0.1 10 Test for overall effect: Z = 4.36 (P < 0.0001)	100
Heterogeneity: Tau ² = 0.00; Chi ² = 0.28, df = 1 (P = 0.60); i ² = 0% Test for overall effect: Z = 4.36 (P < 0.0001) Favours [Sodium Pico] Favours [PEG-ELS]	100
Test for overall effect: Z = 4.36 (P < 0.0001) Favours [Sodium Pico] Favours [PEG-ELS]	100
68x13mm (300 x 300 DPI)	

hudy or Subarous	Normal salin			Moight	Risk Ratio	Risk Ratio
tudy or Subgroup umar 2013	Events To 14	15 15	10101	24.2%	M-H, Random, 95% Cl 0.94 [0.78, 1.12]	
nha 2007	37	40 53	55	75.8%	0.96 [0.87, 1.06]	
otal (95% CI) otal events	51	55 68	70	100.0%	0.95 [0.87, 1.04]	
eterogeneity: Tau² = est for overall effect:			= 0.81)	; I ² = 0%		0.7 0.85 1 1.2 1.5 Favours [PEG] Favours [Normal saline]
			67x	12mn	n (300 x 300 E	OPI)

Study or Subgroup	NaP Events Total Ev	PEG ents Total Weigt	Risk Ratio nt M-H, Random, 95% Cl	Risk Ratio M-H, Random, 95% Cl
Da Silva 1997 Gremse 1996 Total (95% CI)	10 15 18 19 34	11 15 50.49 8 15 49.69 30 100.00	% 1.78 [1.09, 2.89]	
Total events Heterogeneity: Tau ² = Test for overall effect:	28 0.17; Chi ² = 3.81, dt	19		0.1 0.2 0.5 1 2 5 Favours [NaP] Favours [PEG]
		64x13mi	n (300 x 300 D	PI)

1 2	
3	
4 5	
6 7	
8	
9 10	
11 12	
13	
14 15	
16	
17	
19 20	
21	
22 23	
24 25	
26	
27 28	
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 4\end{array}$	
31	
31 32 33 34 35 36 37 38 39	
34 25	
35 36	
37 38	
40 41	
42 43	
44	
45 46	
47 48	
49	
50 51	
52 53	
54	
55 56	
57 58	
00	

60

Appendix 1 - Search strategy

vid EMBASE 1974 to 16 July 2016

- 1. exp colonoscopy/ OR colonoscop*.mp.
- 2. Surgery OR procedure
- 3. 1 or 2
- 4. infant/
- 5. child/
- 6. school child/
- 7. adolescent/
- 8. (infant* or child* or pediatric* or paediatric* or adolescent* or neonat* or toddler or young).mp.
- 9. 4 or 5 or 6 or 7 or 8
- 10. colon lavage/
- 11. intestine preparation/
- 12. exp laxative/
- 13. exp macrogol derivative/
- 14. exp phosphate/
- 15. exp citric acid/
- 16. exp magnesium oxide/
- 17. exp bisacodyl/
- 18. exp organometallic compound/
- 19. exp sulfate/
- 20. exp anthraquinone derivative/
- 21. exp enema/

22. (cathartic* or polyethylene glycol* or laxative* or phosphate* or citrate* or magnesium oxide* or bisacodyl or organometallic compound* or sulfat* or anthraquinone* or enema or bowel preparation or bowel cleansing or PEG-ELS or macrogol* or senna or docusate sodium or Sodium picosulphate or Cascara or casanthranol or Buckthorn or senokot or Aloe Vera or aloin Phenolphthalein or Dulcolax or stimulant or osmotic).mp.

23. (Miralax or Transipeg or Movicol or Forlax or Idrolax or GoLytely or PMF-100 or Golitely or Nulitely or Fortans or TriLyte or Colyte or lactulose or disaccharide or Apo-Lactulose or Chronulac or lactitol or sorbitol or Generlac or Cephulac or Cholac or Constilac or Enulose or Cilac or Heptalac or Actilax or Duphalac or Kristalose or Citroma or Osmoprep or Visicol).mp.

24. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23

- 25. 3 and 9 and 24
- 26. CROSSOVER PROCEDURE.sh.
- 27. DOUBLE-BLIND PROCEDURE.sh.
- 28. SINGLE-BLIND PROCEDURE.sh.
- 29. (crossover* or cross over*).ti,ab.
- 30. placebo*.ti,ab.
- 31. (doubl* adj blind*).ti,ab.
- 32. allocat*.ti,ab.
- 33. trial.ti.
- 34. RANDOMIZED CONTROLLED TRIAL.sh.
- 35. random*.ti,ab.
- 36. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
- 37. (exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans or man or men or wom?n).ti.)

38. 36 not 37 39. 25 and 38

Bowel preparation for elective procedures in Children: A Systematic Review and meta-analysis

Journal:	BMJ Paediatrics Open
Manuscript ID	bmjpo-2017-000118.R2
Article Type:	Original article
Date Submitted by the Author:	18-Jul-2017
Complete List of Authors:	Gordon, Morris; University of Central Lancashire, Karlsen, Fiona; Blackpool Victoria Hospital Isaji, Sahira; Blackpool Victoria Hospital Ong, Teck Guan; Blackpool Victoria Hospital
Keywords:	Evidence Based Medicine, Gastroenterology



Bowel preparation for elective procedures in Children: A Systematic Review and meta-analysis

Morris Gordon (1,2), Fiona Karlsen (2), Sahira Isaji (2), Guan-ong Teck (2)

- 1. School of Medicine and Dentistry, University of Central Lancashire, Preston UK
- 2. Department of Paediatrics, Blackpool Victoria Hospital, Blackpool, UK

Contact information :

Dr Morris Gordon

HA118 Harrington building

University of Central Lancashire

Preston

UK

Email: mgordon@uclan.ac.uk

Phone ++44 1253 300000

Word count: 3621 (including tables)

Keywords: Bowel preparation, Bowel clearance, colonoscopy, systematic review

Funding: None

What is known about the subject

- Bowel preparation is vital to imaging and surgery in young people, but it is key to consider tolerability as well as efficacy in these patients
- Previous systematic reviews have only considered preparation for imaging and limit the age range, despite paediatricians often caring for children till older.

What this study adds

- Despite many trials, there is much clinical heterogeneity and risk of bias concerns with the evidence base, as well as poor safety and tolerability reporting.
- There is evidence that PEG regimens are effective. However, when compared, sodium picosulphate was better tolerated than PEG
- Future research needs to address these key methodology issues and also consider safety and tolerability, as well as efficacy.

Abstract

Objective: Adequate bowel preparation is crucial for both surgery and imaging in young people. Whilst systematic reviews have considered preparation for colonoscopy, they do not consider surgical interventions and to the age of 16, despite it being normal practice for paediatric gastroenterologists to care for transitioning children till older. We carried out a systematic review investigating the optimum bowel preparation agents for all indications in children and young people.

Design: A Cochrane format systematic review of randomised controlled trials (RCTs). Data extraction and assessment of methodological quality were performed independently by two reviewers. Methodological quality was assessed using the Cochrane risk of bias tool.

Patients: Young people requiring bowel preparation for any elective procedure, as defined by the primary studies.

Interventions: RCTs comparing bowel preparation with placebo or other interventions.

Main outcome measures: Adequacy of bowel preparation, tolerability and adverse events.

Results: The search yielded 2124 results and 15 randomised controlled studies (n = 1435), but heterogeneity limited synthesis. Meta-analysis of 2 studies comparing PEG with sodium phosphate showed no difference in the quality of bowel preparation (RR 1.27 [95% CI, 0.66-2.44]). Two studies comparing sodium picosulphate / magnesium citrate with PEG found no difference in bowel preparation, but significantly higher number of patients needing nasogastric tube insertion in the PEG-ELS (RR 0.04 [95% CI, 0.01-0.18], 45 of 117 in PEG group vs 2 of 121 in Sodium picosulphate group). Meta-analysis of 3 studies (n = 241) found no difference between PEG and Sennasoids (RR 0.73 [95% CI, 0.31-1.71]).

Conclusions: The evidence base is clinically heterogeneous and methodologically at risk of bias. There is evidence that all regimens are equally effective. However, sodium picosulphate was better tolerated than PEG. Future research is needed with all agents and should seek to consider safety and tolerability, as well as efficacy.

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

Background:

Bowel imaging is a crucial modality in the diagnosis and monitoring of Inflammatory Bowel Disease (IBD), as well as surgery frequently being required in such patients. Multiple studies have suggested that bowel preparations must be individually tailored according to patient age, size and clinical status.¹ However, currently there is no internationally recognised gold standard regimen for paediatric bowel preparations.² Several regimens have been tried with the aim of identifying the safest, efficacious and tolerable combination, with varying success.³

Bowel preparation regimens can be based on lavage (bowel clean out) or cathartics (agents that accelerates defecation). Examples included; large volume of polyethylene glycol-electrolyte (PEG-ELS) lavage solution, sodium phosphate (an oral, low-volume, hyperosmotic agent), sodium pico-sulphate, bisacodyl and dietary measures, such as diet packs or clear liquid diets (often in combination with other agents).

Adequate bowel preparation prior to such procedures is crucial to ensure complete visualisation of the colonic mucosa (thus successful diagnostic and therapeutic colonoscopy, endoscopy and capsule endoscopy) and to minimize the risk of possible contamination during surgery. Administration of the agents is much more problematic in children compared to adults who manage to take the agents readily. In un-cooperative children, use of a naso-gastric tube to administer the agents has been reported to be an effective method to guarantee bowel wash out.⁴ Reduced tolerance can result in poor outcomes due to inadequate preparation, increased rate of complications, extended procedural time and missed lesions.³ Additionally, side effects have previously been noted, such as hyperphosphataemia in children who receive sodium phosphate.⁴

Whilst previous reviews have considered preparation for colonoscopy³, they do not always consider surgical interventions and often limit their populations at the age of 16, despite it being normal practice for paediatric gastroenterologists to look after such patients for a number of years before transition to adult services.⁵

We carried out an up to date systematic review using the Cochrane collaboration format to summarise the available evidence investigating the optimum bowel preparation agents for all indications in children and young people.

Methods:

The objectives of this review were to evaluate the efficacy and safety of different bowel preparation for young people for any indication. A full protocol for the study was completed by the authors prior to commencement of the study and is available on request. This set out the procedure for the search, study screening, data extraction, risk of bias evaluation and analysis.

Criteria for considering studies for this review

RCTs were included in this systematic review. Participants were aged 0 to 21 years. This age range was selected after a scoping search and discussion with local stakeholders (tertiary centres) confirmed that it can be normal practice in pediatric gastroenterology for these patient groups to have variable transition to adult services, but 21 years was agreed as an absolute cut off and reflected several studies that would otherwise be excluded. Studies with adults included that did not allow analysis of this Paediatric age range were excluded. Studies compared bowel preparation with another bowel preparation or placebo, with all forms and dosing regimens considered. The purpose of bowel clearance was for colonoscopy or elective surgery. Studies were excluded if the purpose was to treat faecal impaction or encopresis. The primary outcome measure for the studies was the number of adequate bowel preparations, as defined by the included studies. Secondary outcomes included: tolerability (the propoprtion of children who could take the given therapy without the need for support through a nasogastric tube or incomplete dosing), Duration of procedure, Missed lesions due to inadequate bowel preparation and occurrence of any adverse events.

Search methods for identification of studies

Electronic searches (search strategy not limited by language) were completed of MEDLINE, The Cochrane Central Register of Controlled Trials, EMBASE and CINAHL (Inception- 15 July 2016), Appendix 1. References of included trials were also searched. Manufacturers were contacted to identify further negative and unpublished research. Abstracts were considered for inclusion if full details to judge inclusion were offered or available from the authors after contact by the study team.

Data extraction and assessment of methodological quality of included studies were independently performed by 2 authors and disagreements solved with involvement of the third author.

All identified abstracts and results from searches were reviewed by the authors. If the reference appeared relevant, a full copy of the study was obtained. After reading the full texts, each author independently assessed the eligibility of all trials identified based on the inclusion criteria above. Disagreement among authors was discussed and agreement reached by consensus. If the data to judge inclusion were unclear, attempts were made to contact the authors.

A data extraction form was developed and piloted to extract information on relevant features and results of all primary and secondary outcomes of included studies. The two reviewers separately extracted and recorded data on the predefined checklist, with disagreement discussed and consensus reached.

The risk of bias of selected trials was assessed independently by the authors using the Cochrane risk of bias tool with disagreement once again resolved by reaching consensus. Study authors were contacted for further information when insufficient information was offered to judge risk of bias or data were missing for primary outcomes. Analysis was completed using Revman (Review Manager 5.2, V.5.2.9, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2012).

The primary outcome—efficacy of bowel preparation agents—was assessed using the Risk Ratio (RR) with 95% CI. The secondary outcomes were assessed by calculating the risk ratio (RR) and 95% CI or the MD with 95% CI, as indicated. The authors of included studies were again contacted to supply any missing data. Heterogeneity among trial results was assessed by inspection of graphical presentations and by calculating the χ^2 test of heterogeneity (a p value of 0.10 was regarded as statistically significant). We also used the I2 statistic to quantity the effect of heterogeneity.¹² A result of less than 25% was defined as low, upto 75% moderate and above 75% high heterogeneity. A random-effects model was used, with a sensitivity analysis with the fixed-effects model, to identify differences in results that would suggest heterogeneity.

Results:

The electronic database search identified 2124 studies that were screened for inclusion. Of these, 15 studies (n = 1435) were judged to be potentially relevant and subjected to full text review (Figure 1). Only 12 papers needed consideration of a third author (less than 1%) to reach consensus, with one included and 11 excluded. Experts were contacted, but no extra reports were received and no further studies were identified from drug companies.

Description of studies

Excluded studies

Nine reports were excluded for failing to meet the inclusion criteria. Five were not solely with patients under 21 years of age, three were not RCTs and one was an abstract with insufficient data to judge inclusion.

Included studies

The 15 RCTs included described various regimens and comparative agents, with nine included in quantitative analysis (Table 1) and the remaining six in qualitative analysis (Table 2). Four studies compared various different regimens and combinations of PEG, Two compared polyethylene glycol (PEG) with oral sodium phosphate, two compared PEG with Normal Saline, three compared multiple combinations of PEG, sennasoids and sodium picosluphate, two diet kits with sodium phosphate, one study compared sodium picosulphate with phosphate enemas and one sodium picospulphate with PEG.



Study	Year	No	Age	Regimen 1	Regimen 2	Regimen 3	Regimen 4	Context	Randomisation	Allocation Concealment	Blinding	Incomplete Outcomes	Selective reporting	Other
Gremse et al	1996	34	3 years - 17 years	Sodium Phosphate	PEG	N/A	N/A	Elective Colonoscopy	Unclear - one of the authors randomised patients into groups	One of the authors assigned the patients to their groups, also perform colonoscopies	Appear Single Blind	Unclear, no ITT	High – Details of adverse events not given	None
Sinha et al	2007	126	Mean 3 years	Sodium Chloride	PEG	Ringer Lactate	N/A	Elective surgery	Unclear	Unclear	Appear Single Blind	Low risk	Unclear risk	None
Kierkus et al	2013	240	10 years – 18 years	BPEG	PEG	Sennosides	N/A	Elective colonoscopy	List Created by independent person using block	Yes	Single Blind	Low risk	Low Risk	None
Kumar et al	2013	30	1 month – 7 years	Normal Saline	PEG	N/A	N/A	Various surgical procedures	Unclear	Unclear	Unclear	Low risk	Low	None apparent
Turner et al	2009	83	4 years – 18 years	Pico-Salax	PEG-ELS	N/A	N/A	Elective colonoscopy	Computer- generated list in blocks of 6	Yes	Single Blind	Yes	Low risk	Funded by pharma but not involved in study
Di Nardo et al	2014	299	2 years – 18 years	PEG-ELS with simethicone	PEG with citrate and bisacodyl	PEG 3350 with ascorbic acid	Sodium picosulphate, Magesium oxide and citric acid	Elective colonoscopy	Computer generated list	Opaque sealed signed envelop	Unblind	Low Risk	Low risk	None apparent
Dahsan et al	1999	70	3 years – 20 years	Magnesium citrate with X-prep	Dulcolax and Fleet Enema	Golytely (PEG)	N/A	Elective Colonoscopy	No detail given	unclear	Single blind	Low Risk	Low risk	None apparent
Terry et al	2013	33	6 years – 21 years	PEG-P	Senna	N/A	N/A	Elective Colonoscopy	Randomly chosen preparation packet	A nurse administer – no further details	Single Blind	Low risk	Low Risk	None apparent
Da Silva et al	1997	30	3 years – 14 years	Sodium Phosphate	PEG	N/A	N/A	Elective Colonoscopy	Computer generated randomly assigned	Unclear Risk	Unclear Risk	Unclear	High Risk	None apparent

glycol without electrolytes)

https://mc.manuscriptcentral.com/bmjpo

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.

n et alu018 yearsSodium Phosphatecitrate and Sodium phosphatebowe preparations for the two regimens. No safety concerns were raised, but numbers of adverse events were not describedcolonoscopyuSealedsafetyRiskRiskPinfield et al1996318 months - 16 yearsPicolaxBisacodyl + Phosphate enemaBisacodyl + Phosphate enemaBisacodyl + Phosphate enemaBisacodyl + Phosphate enemaElective colonoscopyUnclearSealed envelopesSingle blindHigh Risk - only adverse eventsHigh risk - eventsHigh risk - eventsHigh risk - eventsHigh risk - eventsHigh risk	orting	Selective reporting	Incomplete Outcomes	Blinding	Allocation Concealment	Randomisat ion	Context	Main outcomes reported in the study	Regimen 2	Regimen 1	Age	No	Year	Study
In ct al018 yearsSodium Phosphatecitrate and Sodium phosphatebowe preparations for the two regimens. No safety concerns were raised, but umbers of adverse events were not describedcolonoscopyColonoscopyColonoscopySealedSingle blindHigh Risk – only adverse eventsRiskPinfield 														
Pinfield et al 1999 63 18 moths - 16 years Picolax moths - 16 years Bisacodyl + Phisphate enema Bowel preparation was good or excellent in all of the patients in the Dicolax group, in all of the patients in the bisacodyl phosphate enema group(n=31). Abdominal disconfirt was reported by 7 in the picolax group vs 18 in the bisacodyl group and vomiting by 3 in the picolax group and 0 in the bisacodyl group and 0 in the picolax group and 0 in the bisacodyl group and 0 in the bisacodyl protocol PEG 3350 + EG 3350 Lettice al Computer generated random list Sealed envelopes Single blind High Risk - only adverse events High risk only adverse events N Elective al 2013 93 Mean 10yrs 4 day protocol 2350 2-day protocol 3350 2-day protocol PEG 3350 2-day protocol due to side effects Elective Colonoscopy Computer generated random list unclear unclear unclear low risk blind Low risk Low risk <td></td> <td></td> <td>Unclear</td> <td>Unclear</td> <td>Unclear</td> <td>Unclear</td> <td></td> <td>bowel preparations for the two regimens. No safety concerns were raised, but numbers of adverse events were not</td> <td>citrate and Sodium</td> <td>Sodium</td> <td>· ·</td> <td></td> <td>1996</td> <td></td>			Unclear	Unclear	Unclear	Unclear		bowel preparations for the two regimens. No safety concerns were raised, but numbers of adverse events were not	citrate and Sodium	Sodium	· ·		1996	
al10yrsprotocolprotocol PEG 3350in 57.5% of regimen 1 and 73.6% of regimen 2. Side effects were reported as minimal and comparable in both groups (abdominal pain: 26%-32%, vomiting: 2%). None of the children discontinued his protocol due to side effectsColonoscopygenerated random listLow riskLow r	th risk None appa	High risk	only adverse			Unclear		Bowel preparation was good or excellent in all of the patients in the Picolax group (n=32) compared with 22 patients in the bisacodyl phosphate enema group(n=31). Abdominal discomfort was reported by 7 in the picolax group vs 18 in the bisacodyl group and vomiting by 3 in the picolax	Phosphate	Picolax	months -	63	1999	
al21 years3350 Max 255g3350 max s5g/dayto 18/18 in regimen 1 and 13/14 in regimen 2. Regimen 1 5 reports of minor side effects were made vs 10 reports in regimen 2.ColonoscopygivenblindblindLow RiskLow RiskLow RiskLow RiskLow RiskLow RiskLow RiskLow RiskNaiseNaiseal02 years - 14 years1-day 2g/kg PEG + Bisacodyl2-day 1.5g/kg PEG + BisacodylA grading of excellent or good was given to 35/50 in regimen 1 and 36/50 in regimen 2. Regimen 1 8/18 complained ofElective ColonoscopyComputer generated randomA technician randomly assignSingle blindLow RiskLow Risk Low RiskNai RiskNai Risk RiskNai Risk RiskNai Risk RiskNai RiskNai Risk RiskNai Risk Risk	sh risk None appa	High risk	unclear	unclear	unclear	generated		in 57.5% of regimen 1 and 73.6% of regimen 2. Side effects were reported as minimal and comparable in both groups (abdominal pain: 26%-32%, vomiting: 2%). None of the children discontinued his	protocol PEG 3350 +	protocol		93	2013	
Najafi et al201510 02 years - 14 years1-day 2g/kg PEG + Bisacodyl2-day 1.5g/kg PEG + BisacodylA grading of excellent or good was given to 35/50 in regimen 1 and 36/50 in regimen 2. Regimen 1 8/18 complained ofComputer colonoscopyA technician randomly asignSingle blindLow RiskLow RiskLow RiskLow RiskLow Risk	<i>w</i> risk None appa	Low risk	Low risk		unclear			to 18/18 in regimen 1 and 13/14 in regimen 2. Regimen 1 5 reports of minor side effects were made vs 10 reports in	3350 max	3350		32	2014	
abdominal pain vs 3/14 nausea, 2/14 vomiting and 3/14 of abdominal pain in regimen 2.	w Risk None appa	Low Risk	Low Risk	-	randomly	generated random		to 35/50 in regimen 1 and 36/50 in regimen 2. Regimen 1 8/18 complained of nausea, 1/18 vomiting and 4/18 abdominal pain vs 3/14 nausea, 2/14 vomiting and 3/14 of abdominal pain in	PEG +	PEG +			2015	•
El-Baba et al 2006 62 4 years - 18 years food kit, magnesium citrate Solum Phosphate Solum Phosphate excellent in 50% of regimen 1 and 19% of regimen 2. 30/36 in group 1 reported minor side effects vs 26/26 in group 2.	w risk None appa	Low risk	Unclear		Unclear	random number		excellent in 50% of regimen 1 and 19% of regimen 2. 30/36 in group 1 reported		food kit, magnesium		62	2006	

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

Seven studies were rated as low risk for random sequence generation (selection bias) because these studies employed computer-generated randomisation. The remaining studies described themselves as randomised but, with no further details given or available from authors, were rated as unclear risk of bias.

Five studies were rated as low risk of bias for allocation concealment (selection bias). Nine remaining studies were rated as unclear risk of bias for allocation concealment as the methods were not clearly described in the manuscripts. One described the allocated researcher as performing colonoscopies and was rated as high risk.

Ten studies were blinded and were judged to be at low risk of bias for blinding of personnel (performance bias) for such an intervention. Four studies described themselves as blinded, but gave no further details so was rated as unclear risk of bias. One study was open-label and judged to be at high risk of bias for blinding.

Eight studies reported full and appropriate data and satisfactorily documented withdrawals and dropouts and were therefore judged to be at low risk of bias for incomplete outcome data (attrition bias) and nine were judged as low risk for selective reporting (reporting bias). Two studies did not record full data for all patients and were judged high risk of bias for attrition bias. Four studies did not offer outcome data regarding side effects and tolerability so were judged at high risk for reporting bias.

All studies were judged to be at low risk for other sources of bias. However, the small sample sized of many of these studies is concerning, suggesting they were pilot or similarly underpowered studies, raising a further concern regarding bias. Details are summarised in Table 1.

The 15 studies present significant clinical and methodological heterogeneity (Table 1) and this severely limits the scope for synthesis.

PEG vs Sennasoids

Meta-analysis of 3 studies (n = 241)^{6,7,8} found no difference between polyethylene glycol (PEG) and Sennasoids in adequate bowel preparation (RR 0.73 [95% CI, 0.31-1.76], Figure 2). High statistical heterogeneity was noted. Data regarding tolerability and safety was not presented to allow synthesis.

Sodium picosulphate and magnesium citrate versus polyethylene glycol-electrolyte lavage solution (PEG-ELS)

Within these two studies versus PEG-ELS^{9,10}, equivocal adequacy of bowel preparation was seen (RR 0.99 [95% CI, 0.89-1.11], Figure 3). PEG's acceptability was reportedly poorer than sodium picosulphate in both studies. Meta-analysis of two PEG-ELS studies using the random effects model found a significantly higher number of patients needing nasogastric tube insertion in the PEG-ELS group (45 of 117) than the sodium picosulphate group (2 of 121), (RR 0.04 [95% CI, 0.01-0.18], Figure 4).

One patient in the PEG-ELS group and one in the sodium picosulphate group in the two studies were assessed as dehydrated and required intravenous (IV) fluids. For the PEG-ELS patient, a 10-year-old girl is reported who required intravenous fluid for 6 hours because of lethargy and dehydration (dryness of the oral mucosa and orthostatic hypotension) with serum electrolyte and glucose serum levels within the normal range. For the child in the sodium picosulphate group, a 12-year-old girl is reported that required intravenous fluids for 2 hours due to mild lethargy post procedure and was discharged well thereafter. Her vital signs were always within normal limits, but her serum osmolality was 316 mosm/L; she had drunk only two glasses of apple juice during the entire duration of the bowel cleanout. No other serious adverse events were noted.

PEG vs Normal Saline

Meta-analysis of 2 studies (n = 125) comparing PEG with normal saline^{11,12} found no difference in rate of adequate bowel preparation (RR 0.95 [95% CI, 0.87-1.04], Figure 5). Adverse events were not reported homogenously to allow analysis, but occurred in both groups, including abdominal pain and vomiting.

PEG vs Sodium phosphate

There were two studies concerning 63 participants.^{4,13} Meta-analysis of 2 studies using the randomeffect model found no difference in the adequacy of bowel preparation (RR 1.27 [95% CI, 0.66-2.45], Figure 6). Again, high statistical heterogeneity was noted. One of the studies needed to insert a nasogastric tube in all patients receiving PEG, while in the remaining study, 53% of participants in the PEG group were unable to finish taking the solution whilst all the patients in the sodium phosphate group could complete the medication. As these were reported differently, no meta-analysis was performed. No serious adverse events were reported.

Other studies

Within the remaining studies^{1, 14-18} no meta-analysis was possible. However, no individual study found any different in adequacy of bowel preparation or adverse events. Tolerability was not well reported across studies. Whilst secondary outcome analysis for further items were planned, data was not presented to allow this to take place.

Discussion:

Despite the common requirement for bowel preparation in young people, the results of this review have highlighted a very poor evidence base. A mixture of clinical heterogeneity related to multiple agent regimens and methodological heterogeneity limiting the ability for meta-analysis has significantly limited synthesis. In multiple small analyses, PEG-ELS, Senna, Normal Saline, Sodium phosphate and Sodium picosulphate / Magnesium citrate found no difference in adequacy of bowel preparation. This was similar across the remaining individual studies. As such, despite the significant weaknesses of the evidence base, it is worth noting that no difference in adequacy of bowel preparation has been reported in any included study. This was also the case with adverse events, although it must be noted these were reported in an extremely heterogeneous fashion, with individual minor, major and patient overall recording of events across studies.

Of note, there was a significant difference in favour of sodium pico-sulphate and magnesium citrate regarding tolerability, specifically the need for a nasogastric tube to complete the bowel preparation. This is a particularly interesting finding, as the primary studies highlighted that whilst tolerability of PEG was extremely poor, smaller volumes than planned appeared to have little impact on efficacy. This raises the question of the need for the nasogastric tube at all and so this may need further investigation in the future. Sodium pico-sulphate was also compared to bisacodyl and a phosphate enema in a single study with equivocal preparation, tolerability and safety reported.

PEG appeared to be the least tolerable agent across all studies - with a number of the patients requiring a nasogastric tube insertion, but this is from qualitative synthesis of individual studies, with this outcome reported in heterogeneous fashion so meta-analysis was not possible. Additionally, as the age ranges of included participants varied greatly, it is hard to make firm conclusions on this finding as the need for nasogastric tubes is likely to be very age dependent. Oral sodium phosphate was well tolerated in individual studies. Despite the satisfactory tolerability and safety profile of sodium phosphate, it should be noted that care must be taken when using this agent as it can cause significant electrolyte imbalances. As such, it should not be used in patients with deranged baseline electrolytes, suboptimal renal and hepatic function, as it poses a risk of acute kidney injury and phosphate nephropathy.¹⁹

With all the agents studied the occurrence of minor adverse events such as abdominal pain, bloating, faecal incontinence, nausea, vomiting, headaches and anal irritation was comparable. No serious adverse events were reported in any of the studies. It should also be noted that in the context of elective surgery, there is growing recognition of the role for proceeding without bowel preparation.²⁰

The evidence base for this review covers a large number of trials with a reasonable number of patients, but is severely limited due to clinical and methodological heterogeneity, as well as concerns with risk of bias. As such, the findings of this review should be interpreted with extreme caution as it is difficult to draw firm conclusions for any of the investigated agents. it must also be noted that for the primary outcome, successful bowel preparation was 'as defined' by primary studies, with several different scoring systems and criteria used. This also limits the appropriateness of meta-analysis in this context, although those wishing to complete future studies should note the Ottawa scoring system²¹ was the only such scoring method reported in multiple studies. This is also true of adverse events, which were reported in a sporadic and inconsistent manner that prevented comment on even simple complaints, such as nausea or vomiting.

Considering the small sample sizes, the high degree of heterogeneity and a wide variation in the regimen of each cleansing agent; the findings of this review cannot be reliably used to inform clinical practise, but most usefully should inform future research. In particular, as the question of adequacy of bowel preparation has been established as essentially equivocal amongst all study agents, a shift of focus for future studies is needed. Given the unique needs of a paediatric population, considering the issue of tolerability as a primary outcome is vital and looking at the lower volume options presented as enteral agents could offer potential practical advantages and need a high quality study to investigate them.

Conclusions:

The publishing evidence base investigating this issue is large, but is clinically heterogeneous and at risk of bias. All regimens appear equivocal for adequacy of bowel preparation. However, when compared with sodium pico-sulphate, sodium pico-sulphate is better tolerated. Future research should seek to consider safety and tolerability, as well as efficacy, given the key importance of these issues in a childhood population.



Figure legend

Fig 1: Patient flow diagram

Fig 2: Forest plot for PEG vs Senna, adequacy of bowel preparation

Fig 3: Forest plot for Sodium picosulphate and magnesium citrate versus polyethylene glycolelectrolyte lavage solution (PEG-ELS), adequacy of bowel preparation

Fig 4: Forest plot for Sodium picosulphate and magnesium citrate versus polyethylene glycolelectrolyte lavage solution (PEG-ELS), Tolerability of agent

Fig 5: Forest plot for PEG vs Normal Saline, adequacy of bowel preparation

Fig 6: Forest plot for PEG vs Sodium Phosphate, adequacy of bowel preparation

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright


- 1. Trautwein AL, Vinitski LA, Peck SN. Bowel preparation before colonoscopy in the pediatric patient: A randomised study. *Gastroenterol Nurs* 1996;**19**:137–9.
- 2. Engum SA, Carter ME, Murphy D, Breckler FM, Schoonveld G, Grosfeld JL. Home bowel preparation for elective colonic procedures in children: Cost savings with quality assurance and improvement. J Pediatr Surg 2000;35:232-4.
- Pall H, Zacur GM, Kramer RE, et al. Bowel preparation for pediatric colonoscopy: report of the NASPGHAN endoscopy and procedures committee. J Pediatr Gastroenterol Nutr 2014;59:409-16.
- Gremse DA, Sacks AI, Raines S. Comparison of oral sodium phosphate to polyethylene glycol-based solution for bowel preparation for colonoscopy in children. J Ped Gastroenterol Nutr 1996;23:586-90.
- Hunter A, Mamula P. Bowel preparation for pediatric colonoscopy procedures. J Pediatr Gastroenterol Nutr. 2010;3:254-61.
- Terry NA, Chen-Lim ML, Ely E, Jatla M, Ciavardone D, Esch S, Farace L, Jannelli F, Puma A, Carlow D, Mamula P. Polyethylene Glycol Powder Solution Versus Senna for Bowel Preparation for Colonoscopy in Children. J Pediatr Gastroenterol Nutr 2013;56:215-9.
- Kierkus J, Horvath A, Szychta M, Woynarowski M, Wegner A, Wiernicka A, Dadalski M. High-versus Low-Volume Polyethylene Glycol Plus Laxatives versus Sennosides for Colonoscopy preparation in children. JPGN, Vol 57, 2. 2013.
- Dahshan A, Lin CH, Peters J, Thomas R, Tolia V. A Randomized, Prospective Study to Evaluate the Efficacy and Acceptance of Three Bowel Preparations for Colonscopy in Children. The American Journal of gastroenterology, (1999), 94.

BMJ Paediatrics Open

- Di-Nardo G, Aloi M, Cucchara S, Spada C, Hassan C, Civitelli F, Nuti F, Ziparo C, Pession A, Lima M, Torre G and Oliva S. Bowel Preparations for Colonoscopy: An RCT. American academy of paediatrics. 2014;10:1542
- Turner D, Benchimol E, Dunn H, Griffith A.M, Frost K, Scaini V, Avolio J, Ling SC. Pico-Salax versus polyethylene glycol for bowel cleanout before colonoscopy in children: a randomized controlled trial. Endoscopy 2009;41:1038-1045.
- 11. Kumar A, Hussain A. Preoperative bowel preparation in children: polyethylene glycol versus normal saline. African journal of paediatric surgery. 2013:10; 235-238.
- Sinha K, Kanojia RP, Rawat JD, Wakhlu A, Kureel SN, Tandon RK, Verma A. Comparison of three solutions for total gut irrigation in pediatric patients. Pediatr Surg Int. 2007;23:581-584.
- Da Silva MM, Briars GL, Patrick MK, Cleghorn GJ, Shepherd RW. Colonoscopy preparation in children: safety, efficacy and tolerance of high-versus low-volume cleansing methods. J Ped Gastroenterol Nutr. 1997;24:33-7.
- 14. Pinfield A, Stringer M. Randomised Trial of two pharmacological methods of bowel preparation for day case colonscopy. Arch Dis Child. 1999; 80:181-183.
- 15. Najafi M, Hossein G, Motamed F, Farahmand F, Khodadad A, Ghajarzadeh M, Rezaei N, Mehrabani S. Comparison of one and two-day bowel preparation with polyethylene glycol in pediatric colonscopy. Turk J Gastroenterol 2015; 26: 232-5.
- 16. Sorser S, Konanki V, Hursh A, Hagglund K and Lyons H. 1-day bowel preparation with polyethylene glycol 3350 is as effective and safe as a 3-day preparation for colonscopy in children. BMC Research Notes, 7:648, 2014.
- Elitsur R, Butcher L, Vicki L, Elitsur Y. Polyethylene glycol 3350 based colon cleaning protocol: 2 d vs 4 d head to head comparison. World J Gastrointest Endosc (2013) 16; (4): 165-168.
- El-Baba M.F, Padilla M, Houston C, Madani S, Lin CH, Thomas R, Toila V. A prospective study comparing oral sodium phosphate solution to a bowel cleansing preparation with nutrition food package in children. J Pediatr Gastroenterol Nutr 2006; 42:174–177

- 19. US Food and Drug administration (FDA). FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation.

<text><text>




bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.

-	
2	
3	
2 3 4 5 6 7 8 9 10	
7	
5	
6	
7	
~	
8	
9	
10	
10	
11	
12	
13	
10	
14	
15	
16	
10	
17	
18	
10	
13	
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 8 29 30 132 33 435 36 37 839	
21	
22	
22	
23	
24	
25	
25	
26	
27	
20	
20	
29	
30	
21	
51	
32	
33	
24	
34	
35	
36	
27	
31	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
49	
50	
51	
52	
52	
53	
54	
55	
00	
56	
57	
58	
20	
59	
~~	

60

1



64x14mm (300 x 300 DPI)

Study or Subgroup	Sodium Events		PEG E		Weight	Risk Ratio M-H, Random, 95% Cl	Risk Ratio M-H, Random, 95% Cl
Di Nardo 2014 Furner 2009	66 33	75 46	65 32	74 43	81.8%	1.00 [0.89, 1.13] 0.96 [0.75, 1.24]	
Fotal (95% CI) Fotal events Heterogeneity: Tau² = Fest for overall effect	99 = 0.00; Chi : Z = 0.09 (121 ² = 0.08, P = 0.92	97 df=1 (F !)		100.0% '); I ² = 0%		0.01 0.1 10 100 Favours (Sodium Pico) Favours (PEG-ELS)
				68	x13m	ım (300 x 300	DPI)

1	
2	
3 4 5 6 7	
4	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
$\begin{array}{c} 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 223\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39 \end{array}$	
22	
23	
24	
20	
20	
21	
20	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43 44	
44 45	
45 46	
40 47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59 60	
60	

60

1

Sodium Pico PEG ELS Risk Ratio Risk Ratio Di Nardo 2014 1 75 15 74 48.7% 0.07 [0.01, 0.49] Turner 2009 1 46 30 43 51.3% 0.03 [0.00, 0.22] Total (95% CI) 121 117 100.0% 0.04 [0.01, 0.18] Total (95% CI) 2 45 Heterogeneity: Tau ² = 0.00; Chi ² = 0.28, df = 1 (P = 0.60); P = 0% 0.01 0.1 1 10 Test for overall effect: Z = 4.36 (P < 0.0001) 68x13mm (300 x 300 DPI) 68x13mm (300 x 300 DPI) 68x13mm (300 x 300 DPI) 68x13mm (300 x 300 DPI)	100
Di Nardo 2014 1 75 15 74 48.7% 0.07 [0.01, 0.49] Turner 2009 1 46 30 43 51.3% 0.03 [0.00, 0.22] Total (95% Cl) 121 117 100.0% 0.04 [0.01, 0.18] Total events 2 45 Heterogeneity: Tau ² = 0.00; Chi ² = 0.28, df = 1 (P = 0.60); P = 0% Test for overall effect: Z = 4.36 (P < 0.0001) Favours [Sodium Pico] Favours [PEG-ELS]	100
Total (95% Cl) 121 117 100.0% 0.04 [0.01, 0.18] Total events 2 45 Heterogeneity: Tau ² = 0.00; Chi ² = 0.28, df = 1 (P = 0.60); i ² = 0% 0.01 0.1 10 Test for overall effect: Z = 4.36 (P < 0.0001)	100
Heterogeneity: Tau ² = 0.00; Chi ² = 0.28, df = 1 (P = 0.60); i ² = 0% Test for overall effect: Z = 4.36 (P < 0.0001) Favours [Sodium Pico] Favours [PEG-ELS]	100
Test for overall effect: Z = 4.36 (P < 0.0001) Favours [Sodium Pico] Favours [PEG-ELS]	100
68x13mm (300 x 300 DPI)	

hudy or Subarous	Normal salin			Moight	Risk Ratio	Risk Ratio
tudy or Subgroup umar 2013	Events To 14	15 15	10101	24.2%	M-H, Random, 95% Cl 0.94 [0.78, 1.12]	
nha 2007	37	40 53	55	75.8%	0.96 [0.87, 1.06]	
otal (95% CI) otal events	51	55 68	70	100.0%	0.95 [0.87, 1.04]	
eterogeneity: Tau² = est for overall effect:			= 0.81)	; I ² = 0%		0.7 0.85 1 1.2 1.5 Favours [PEG] Favours [Normal saline]
			67x	12mn	n (300 x 300 E	OPI)

Study or Subgroup	NaP Events Total Ev	PEG ents Total Weigt	Risk Ratio nt M-H, Random, 95% Cl	Risk Ratio M-H, Random, 95% Cl
Da Silva 1997 Gremse 1996 Total (95% CI)	10 15 18 19 34	11 15 50.49 8 15 49.69 30 100.00	% 1.78 [1.09, 2.89]	
Total events Heterogeneity: Tau ² = Test for overall effect:	28 0.17; Chi ² = 3.81, dt	19		0.1 0.2 0.5 1 2 5 Favours [NaP] Favours [PEG]
		64x13mi	n (300 x 300 D	PI)

1 2	
3	
4 5	
6 7	
8	
9 10	
11 12	
13	
14 15	
16	
17	
19 20	
21	
22 23	
24 25	
26	
27 28	
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 4\end{array}$	
31	
31 32 33 34 35 36 37 38 39	
34 25	
35 36	
37 38	
40 41	
42 43	
44	
45 46	
47 48	
49	
50 51	
52 53	
54	
55 56	
57 58	
00	

60

Appendix 1 - Search strategy

vid EMBASE 1974 to 16 July 2016

- 1. exp colonoscopy/ OR colonoscop*.mp.
- 2. Surgery OR procedure
- 3. 1 or 2
- 4. infant/
- 5. child/
- 6. school child/
- 7. adolescent/
- 8. (infant* or child* or pediatric* or paediatric* or adolescent* or neonat* or toddler or young).mp.
- 9. 4 or 5 or 6 or 7 or 8
- 10. colon lavage/
- 11. intestine preparation/
- 12. exp laxative/
- 13. exp macrogol derivative/
- 14. exp phosphate/
- 15. exp citric acid/
- 16. exp magnesium oxide/
- 17. exp bisacodyl/
- 18. exp organometallic compound/
- 19. exp sulfate/
- 20. exp anthraquinone derivative/
- 21. exp enema/

22. (cathartic* or polyethylene glycol* or laxative* or phosphate* or citrate* or magnesium oxide* or bisacodyl or organometallic compound* or sulfat* or anthraquinone* or enema or bowel preparation or bowel cleansing or PEG-ELS or macrogol* or senna or docusate sodium or Sodium picosulphate or Cascara or casanthranol or Buckthorn or senokot or Aloe Vera or aloin Phenolphthalein or Dulcolax or stimulant or osmotic).mp.

23. (Miralax or Transipeg or Movicol or Forlax or Idrolax or GoLytely or PMF-100 or Golitely or Nulitely or Fortans or TriLyte or Colyte or lactulose or disaccharide or Apo-Lactulose or Chronulac or lactitol or sorbitol or Generlac or Cephulac or Cholac or Constilac or Enulose or Cilac or Heptalac or Actilax or Duphalac or Kristalose or Citroma or Osmoprep or Visicol).mp.

24. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23

- 25. 3 and 9 and 24
- 26. CROSSOVER PROCEDURE.sh.
- 27. DOUBLE-BLIND PROCEDURE.sh.
- 28. SINGLE-BLIND PROCEDURE.sh.
- 29. (crossover* or cross over*).ti,ab.
- 30. placebo*.ti,ab.
- 31. (doubl* adj blind*).ti,ab.
- 32. allocat*.ti,ab.
- 33. trial.ti.
- 34. RANDOMIZED CONTROLLED TRIAL.sh.
- 35. random*.ti,ab.
- 36. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
- 37. (exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans or man or men or wom?n).ti.)

38. 36 not 37 39. 25 and 38

Bowel preparation for elective procedures in Children: A Systematic Review and meta-analysis

Journal:	BMJ Paediatrics Open					
Manuscript ID	bmjpo-2017-000118.R3					
Article Type:	Driginal article					
Date Submitted by the Author:	10-Aug-2017					
Complete List of Authors:	Gordon, Morris; University of Central Lancashire, Karlsen, Fiona; Blackpool Victoria Hospital Isaji, Sahira; Blackpool Victoria Hospital Ong, Teck Guan; Blackpool Victoria Hospital					
Keywords:	Evidence Based Medicine, Gastroenterology					



Bowel preparation for elective procedures in Children: A Systematic Review and meta-analysis

Morris Gordon (1,2), Fiona Karlsen (2), Sahira Isaji (2), Guan-ong Teck (2)

- 1. School of Medicine and Dentistry, University of Central Lancashire, Preston UK
- 2. Department of Paediatrics, Blackpool Victoria Hospital, Blackpool, UK

Contact information :

Dr Morris Gordon

HA118 Harrington building

University of Central Lancashire

Preston

UK

Email: mgordon@uclan.ac.uk

Phone ++44 1253 300000

Word count: 3621 (including tables)

Keywords: Bowel preparation, Bowel clearance, colonoscopy, systematic review

Funding: None

What is known about the subject

- Bowel preparation is vital to imaging and surgery in young people, but it is key to consider tolerability as well as efficacy in these patients
- Previous systematic reviews have only considered preparation for imaging and limit the age range, despite paediatricians often caring for children till older.

What this study adds

- Despite many trials, there is much clinical heterogeneity and risk of bias concerns with the evidence base, as well as poor safety and tolerability reporting.
- There is evidence that PEG regimens are effective. However, when compared, sodium picosulphate was better tolerated than PEG
- Future research needs to address these key methodology issues and also consider safety and tolerability, as well as efficacy.

Abstract

Objective: Adequate bowel preparation is crucial for both surgery and imaging in young people. Whilst systematic reviews have considered preparation for colonoscopy, they do not consider surgical interventions and to the age of 16, despite it being normal practice for paediatric gastroenterologists to care for transitioning children till older. We carried out a systematic review investigating the optimum bowel preparation agents for all indications in children and young people.

Design: A Cochrane format systematic review of randomised controlled trials (RCTs). Data extraction and assessment of methodological quality were performed independently by two reviewers. Methodological quality was assessed using the Cochrane risk of bias tool.

Patients: Young people requiring bowel preparation for any elective procedure, as defined by the primary studies.

Interventions: RCTs comparing bowel preparation with placebo or other interventions.

Main outcome measures: Adequacy of bowel preparation, tolerability and adverse events.

Results: The search yielded 2124 results and 15 randomised controlled studies (n = 1435), but heterogeneity limited synthesis. Meta-analysis of 2 studies comparing PEG with sodium phosphate showed no difference in the quality of bowel preparation (RR 1.27 [95% CI, 0.66-2.44]). Two studies comparing sodium picosulphate / magnesium citrate with PEG found no difference in bowel preparation, but significantly higher number of patients needing nasogastric tube insertion in the PEG-ELS (RR 0.04 [95% CI, 0.01-0.18], 45 of 117 in PEG group vs 2 of 121 in Sodium picosulphate group). Meta-analysis of 3 studies (n = 241) found no difference between PEG and Sennasoids (RR 0.73 [95% CI, 0.31-1.71]).

Conclusions: The evidence base is clinically heterogeneous and methodologically at risk of bias. There is evidence that all regimens are equally effective. However, sodium picosulphate was better tolerated than PEG. Future research is needed with all agents and should seek to consider safety and tolerability, as well as efficacy.

Background:

Bowel imaging is a crucial modality in the diagnosis and monitoring of Inflammatory Bowel Disease (IBD), as well as surgery frequently being required in such patients. Multiple studies have suggested that bowel preparations must be individually tailored according to patient age, size and clinical status.¹ However, currently there is no internationally recognised gold standard regimen for paediatric bowel preparations.² Several regimens have been tried with the aim of identifying the safest, efficacious and tolerable combination, with varying success.³

Bowel preparation regimens can be based on lavage (bowel clean out) or cathartics (agents that accelerates defecation). Examples included; large volume of polyethylene glycol-electrolyte (PEG-ELS) lavage solution, sodium phosphate (an oral, low-volume, hyperosmotic agent), sodium pico-sulphate, bisacodyl and dietary measures, such as diet packs or clear liquid diets (often in combination with other agents).

Adequate bowel preparation prior to such procedures is crucial to ensure complete visualisation of the colonic mucosa (thus successful diagnostic and therapeutic colonoscopy, endoscopy and capsule endoscopy) and to minimize the risk of possible contamination during surgery. Administration of the agents is much more problematic in children compared to adults who manage to take the agents readily. In un-cooperative children, use of a naso-gastric tube to administer the agents has been reported to be an effective method to guarantee bowel wash out.⁴ Reduced tolerance can result in poor outcomes due to inadequate preparation, increased rate of complications, extended procedural time and missed lesions.³ Additionally, side effects have previously been noted, such as hyperphosphataemia in children who receive sodium phosphate.⁴

Whilst previous reviews have considered preparation for colonoscopy³, they do not always consider surgical interventions and often limit their populations at the age of 16, despite it being normal practice for paediatric gastroenterologists to look after such patients for a number of years before transition to adult services.⁵

We carried out an up to date systematic review using the Cochrane collaboration format to summarise the available evidence investigating the optimum bowel preparation agents for all indications in children and young people. bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

Methods:

The objectives of this review were to evaluate the efficacy and safety of different bowel preparation for young people for any indication. A full protocol for the study was completed by the authors prior to commencement of the study and is available on request. This set out the procedure for the search, study screening, data extraction, risk of bias evaluation and analysis.

Criteria for considering studies for this review

RCTs were included in this systematic review. Participants were aged 0 to 21 years. This age range was selected after a scoping search and discussion with local stakeholders (tertiary centres) confirmed that it can be normal practice in pediatric gastroenterology for these patient groups to have variable transition to adult services, but 21 years was agreed as an absolute cut off and reflected several studies that would otherwise be excluded. Studies with adults included that did not allow analysis of this Paediatric age range were excluded. Studies compared bowel preparation with another bowel preparation or placebo, with all forms and dosing regimens considered. The purpose of bowel clearance was for colonoscopy or elective surgery. Studies were excluded if the purpose was to treat faecal impaction or encopresis. The primary outcome measure for the studies was the number of adequate bowel preparations, as defined by the included studies. Secondary outcomes included: tolerability (the propoprtion of children who could take the given therapy without the need for support through a nasogastric tube or incomplete dosing), Duration of procedure, Missed lesions due to inadequate bowel preparation and occurrence of any adverse events.

Search methods for identification of studies

Electronic searches (search strategy not limited by language) were completed of MEDLINE, The Cochrane Central Register of Controlled Trials, EMBASE and CINAHL (Inception- 15 July 2016), Appendix 1. References of included trials were also searched. Manufacturers were contacted to identify further negative and unpublished research. Abstracts were considered for inclusion if full details to judge inclusion were offered or available from the authors after contact by the study team.

Data extraction and assessment of methodological quality of included studies were independently performed by 2 authors and disagreements solved with involvement of the third author.

Data collection and analysis

All identified abstracts and results from searches were reviewed by the authors. If the reference appeared relevant, a full copy of the study was obtained. After reading the full texts, each author independently assessed the eligibility of all trials identified based on the inclusion criteria above. Disagreement among authors was discussed and agreement reached by consensus. If the data to judge inclusion were unclear, attempts were made to contact the authors.

A data extraction form was developed and piloted to extract information on relevant features and results of all primary and secondary outcomes of included studies. The two reviewers separately extracted and recorded data on the predefined checklist, with disagreement discussed and consensus reached.

The risk of bias of selected trials was assessed independently by the authors using the Cochrane risk of bias tool with disagreement once again resolved by reaching consensus. Study authors were contacted for further information when insufficient information was offered to judge risk of bias or data were missing for primary outcomes. Analysis was completed using Revman (Review Manager 5.2, V.5.2.9, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2012).

The primary outcome—efficacy of bowel preparation agents—was assessed using the Risk Ratio (RR) with 95% CI. The secondary outcomes were assessed by calculating the risk ratio (RR) and 95% CI or the MD with 95% CI, as indicated. The authors of included studies were again contacted to supply any missing data. Heterogeneity among trial results was assessed by inspection of graphical presentations and by calculating the χ^2 test of heterogeneity (a p value of 0.10 was regarded as statistically significant). We also used the I2 statistic to quantity the effect of heterogeneity.¹² A result of less than 25% was defined as low, upto 75% moderate and above 75% high heterogeneity. A random-effects model was used, with a sensitivity analysis with the fixed-effects model, to identify differences in results that would suggest heterogeneity.

Results:

The electronic database search identified 2124 studies that were screened for inclusion. Of these, 15 studies (n = 1435) were judged to be potentially relevant and subjected to full text review (Figure 1). Only 12 papers needed consideration of a third author (less than 1%) to reach consensus, with one included and 11 excluded. Experts were contacted, but no extra reports were received and no further studies were identified from drug companies.

Description of studies

Excluded studies

Nine reports were excluded for failing to meet the inclusion criteria. Five were not solely with patients under 21 years of age, three were not RCTs and one was an abstract with insufficient data to judge inclusion.

Included studies

The 15 RCTs included described various regimens and comparative agents, with nine included in quantitative analysis (Table 1) and the remaining six in qualitative analysis (Table 2). Four studies compared various different regimens and combinations of PEG, Two compared polyethylene glycol (PEG) with oral sodium phosphate, two compared PEG with Normal Saline, three compared multiple combinations of PEG, sennasoids and sodium picosluphate, two diet kits with sodium phosphate, one study compared sodium picosulphate with phosphate enemas and one sodium picospulphate with PEG.



Study	Year	No	Age	Regimen 1	Regime n 2	Regimen 3	Regimen 4	Main outcomes reported in the study	Context	Randomisa tion	Allocation Concealment	Blinding	Incomplete Outcomes	Selective reporting	Other
Gremse et al	1996	34	3 years - 17 years	Sodium Phosphate	PEG	N/A	N/A	The bowel preparation was excellent or good in 18/19 patients in sodium phosphate Group & 6/15 in PEG group. The incidence of vomiting was similar in both groups, but abdominal pain occurred more in PEG group.	Elective Colonosc opy	Unclear - one of the authors randomised patients into groups	One of the authors assigned the patients to their groups, also perform colonoscopies	Appear Single Blind	Unclear, no ITT	High – Details of adverse events not given	None
inha et I	2007	12 6	Mean 3 years	Sodium Chloride	PEG	Ringer Lactate	N/A	Bowel preparation was good in 35/40 in Nacl group, 49/55 in PEG group and 29/31 of lactate group. All three were similar in safety	Elective surgery	Unclear	Unclear	Appear Single Blind	Low risk	Unclear risk	None
Kierkus et al	2013	24 0	10 years - 18 years	BPEG	PEG	Sennoside S	N/A	There were no significant differences found for the proportions of participants with excellent/good (PEG: 35/79, BPEG: 26/79, sennosides 25/76) bowel preparation	Elective colonosc opy	List Created by independe nt person using block	Yes	Single Blind	Low risk	Low Risk	None
(umar et al	2013	30	1 month – 7 years	Normal Saline	PEG	N/A	N/A	Bowel preparation was rated as good/very good in 14/15 in the PEG group and 15/15 in the NS group. More symptomatic complications were noted in the NS group (7) then PEG group (1).	Various surgical procedur es	Unclear	Unclear	Unclear	Low risk	Low	None apparent
furner et al	2009	83	4 years – 18 years	Pico-Salax	PEG-ELS	N/A	N/A	Bowel preparation was judged as good/excellent in 33/43 of picosalax group and 32/40 PEG-ELS group. No significant difference in safety was found between the groups	Elective colonosc opy	Computer- generated list in blocks of 6	Yes	Single Blind	Yes	Low risk	Funded by pharma but not involved in study
Di Nardo et al	2014	29 9	2 years - 18 years	PEG-ELS with simethicon e	PEG with citrate and bisacody I	PEG 3350 with ascorbic acid	Sodium picosulphat e, Magesium oxide + citric acid	No statistical difference was found between any group using the Boston scoring system (P = .910).No serious adverse events occurred in any group.	Elective colonosc opy	Computer generated list	Opaque sealed signed envelop	Unblind	Low Risk	Low risk	None apparent

https://mc.manuscriptcentral.com/bmjpo

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.

Dahsan ¹ et al	1999 7	-	8 years - 20 years	Magnesiu m citrate with X- prep	Dulcolax and Fleet Enema	Golytely (PEG)	N/A	Bowel preparation was rated as excellent in 6/20 of X-prep group, 2/19 dulcolax and 15/31 of PEG group. Statistically more side effects were reported in the PEG group.	Elective Colonosc opy	No detail given	unclear	Single blind	Low Risk	Low risk	None apparer
Ferry et ²¹ Il	2013 3	- 2	o years - 21 vears	PEG-P	Senna	N/A	N/A	Bowel preparation was rated as excellent/good in 14/16 of PEG-P group and 4/14 of the Senna group. Both were well-tolerated by patient- graded ease of preparation.	Elective Colonosc opy	Randomly chosen preparation packet	A nurse administer – no further details	Single Blind	Low risk	Low Risk	None apparei
Da Silva 1 et al	997 3	- :	9 years - 14 vears	Sodium Phosphate	PEG	N/A	N/A	Excellent-to-good colonic cleansing was achieved in 10/14 in sodium phosphate group and 11/15 of PEG group. Patients recorded less discomfort with orally administered Fleet than with high-volume balanced-lavage	Elective Colonosc opy	Computer generated randomly assigned	Unclear Risk	Unclear Risk	Unclear	High Risk	None apparer
(BP	PEG: P	EG co	ombine				•	preparation ve analysis and risk of k glycol; PEG-ELS Polyet			trolyte lavag	e solution;	: PEG – P	Polyethyle	ne
(BP	PEG: P	EG co	ombine	ed with bi			•	ve analysis and risk of t			ctrolyte lavag	e solution;	PEG – P	Polyethyle	ne
(BP	PEG: P	EG co	ombine	ed with bi			•	ve analysis and risk of t			trolyte lavag	e solution;	PEG – P	Polyethyle	ne

Study	Year	No	Age	Regimen 1	Regimen 2	Main outcomes reported in the study	Context	Randomisat ion	Allocation Concealment	Blinding	Incomplete Outcomes	Selective reporting	Other
Trautwei n et al	1996	14 0	5 years – 18 years	X-Pep and Sodium Phosphate	Magnesium citrate and Sodium phosphate	No significant different reported between bowel preparations for the two regimens. No safety concerns were raised, but numbers of adverse events were not described	Elective colonoscopy	Unclear	Unclear	Unclear	Unclear	Unclear Risk	None apparent
Pinfield et al	1999	63	18 months - 16 years	Picolax	Bisacodyl + Phosphate enema	Bowel preparation was good or excellent in all of the patients in the Picolax group (n=32) compared with 22 patients in the bisacodyl phosphate enema group(n=31). Abdominal discomfort was reported by 7 in the picolax group vs 18 in the bisacodyl group and vomiting by 3 in the picolax group and 0 in the bisacodyl group	Elective colonoscopy	Unclear	Sealed envelopes	Single blind	High Risk – only adverse events	High risk	None apparent
Elitsur et al	2013	93	Mean 10yrs	4-day protocol PEG 3350	2-day protocol PEG 3350 + bisacodyl	Adequate colon preparation was reached in 57.5% of regimen 1 and 73.6% of regimen 2. Side effects were reported as minimal and comparable in both groups (abdominal pain: 26%-32%, vomiting: 2%). None of the children discontinued his protocol due to side effects	Elective Colonoscopy	Computer generated random list	unclear	unclear	unclear	High risk	None apparent
Sorser et al	2014	32	2 years – 21 years	1 day PEG 3350 Max 255g	3 day PEG 3350 max 85g/day	A grading of excellent or good was given to 18/18 in regimen 1 and 13/14 in regimen 2. Regimen 1 5 reports of minor side effects were made vs 10 reports in regimen 2.	Elective Colonoscopy	No detail given	unclear	Single blind	Low risk	Low risk	None apparent
Najafi et al	2015	10 0	2 years – 14 years	1-day 2g/kg PEG + Bisacodyl Suppository	2-day 1.5g/kg PEG + Bisacodyl suppository	A grading of excellent or good was given to 35/50 in regimen 1 and 36/50 in regimen 2. Regimen 1 8/18 complained of nausea, 1/18 vomiting and 4/18 abdominal pain vs 3/14 nausea, 2/14 vomiting and 3/14 of abdominal pain in regimen 2.	Elective Colonoscopy	Computer generated random numbers	A technician randomly assign	Single blind	Low Risk	Low Risk	None apparent
El-Baba et al	2006	62	4 years – 18 years	Pre-packaged food kit, magnesium citrate	Sodium Phosphate	Quality of colon cleansing rated as excellent in 50% of regimen 1 and 19% of regimen 2. 30/36 in group 1 reported minor side effects vs 26/26 in group 2.	Elective colonoscopy	Computer random number generator	Unclear	Single Blind	Unclear	Low risk	None apparent
(8	BPEG:	PEG		ed with bisa		in qualitative analysis and risk Polyethylene glycol; PEG-ELS P			ectrolyte lava	age soluti	ion; PEG – P	Polyethy	/lene

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.

BMJ Paediatrics Open

Risk of bias of included studies

Seven studies were rated as low risk for random sequence generation (selection bias) because these studies employed computer-generated randomisation. The remaining studies described themselves as randomised but, with no further details given or available from authors, were rated as unclear risk of bias.

Five studies were rated as low risk of bias for allocation concealment (selection bias). Nine remaining studies were rated as unclear risk of bias for allocation concealment as the methods were not clearly described in the manuscripts. One described the allocated researcher as performing colonoscopies and was rated as high risk.

Ten studies were blinded and were judged to be at low risk of bias for blinding of personnel (performance bias) for such an intervention. Four studies described themselves as blinded, but gave no further details so was rated as unclear risk of bias. One study was open-label and judged to be at high risk of bias for blinding.

Eight studies reported full and appropriate data and satisfactorily documented withdrawals and dropouts and were therefore judged to be at low risk of bias for incomplete outcome data (attrition bias) and nine were judged as low risk for selective reporting (reporting bias). Two studies did not record full data for all patients and were judged high risk of bias for attrition bias. Four studies did not offer outcome data regarding side effects and tolerability so were judged at high risk for reporting bias.

All studies were judged to be at low risk for other sources of bias. However, the small sample sized of many of these studies is concerning, suggesting they were pilot or similarly underpowered studies, raising a further concern regarding bias. Details are summarised in Table 1.

The 15 studies present significant clinical and methodological heterogeneity (Table 1) and this severely limits the scope for synthesis.

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

PEG vs Sennasoids

Meta-analysis of 3 studies $(n = 241)^{6.7.8}$ found no difference between polyethylene glycol (PEG) and Sennasoids in adequate bowel preparation (RR 0.73 [95% CI, 0.31-1.76], Figure 2). High statistical heterogeneity was noted. Data regarding tolerability and safety was not presented to allow synthesis.

Sodium picosulphate and magnesium citrate versus polyethylene glycol-electrolyte lavage solution (PEG-ELS)

Within these two studies versus PEG-ELS^{9,10}, equivocal adequacy of bowel preparation was seen (RR 0.99 [95% CI, 0.89-1.11], Figure 3). PEG's acceptability was reportedly poorer than sodium picosulphate in both studies. Meta-analysis of two PEG-ELS studies using the random effects model found a significantly higher number of patients needing nasogastric tube insertion in the PEG-ELS group (45 of 117) than the sodium picosulphate group (2 of 121), (RR 0.04 [95% CI, 0.01-0.18], Figure 4).

One patient in the PEG-ELS group and one in the sodium picosulphate group in the two studies were assessed as dehydrated and required intravenous (IV) fluids. For the PEG-ELS patient, a 10-year-old girl is reported who required intravenous fluid for 6 hours because of lethargy and dehydration (dryness of the oral mucosa and orthostatic hypotension) with serum electrolyte and glucose serum levels within the normal range. For the child in the sodium picosulphate group, a 12-year-old girl is reported that required intravenous fluids for 2 hours due to mild lethargy post procedure and was discharged well thereafter. Her vital signs were always within normal limits, but her serum osmolality was 316 mosm/L; she had drunk only two glasses of apple juice during the entire duration of the bowel cleanout. No other serious adverse events were noted.

PEG vs Normal Saline

Meta-analysis of 2 studies (n = 125) comparing PEG with normal saline^{11,12} found no difference in rate of adequate bowel preparation (RR 0.95 [95% CI, 0.87-1.04], Figure 5). Adverse events were not reported homogenously to allow analysis, but occurred in both groups, including abdominal pain and vomiting.

PEG vs Sodium phosphate

There were two studies concerning 63 participants.^{4,13} Meta-analysis of 2 studies using the randomeffect model found no difference in the adequacy of bowel preparation (RR 1.27 [95% CI, 0.66-2.45], Figure 6). Again, high statistical heterogeneity was noted. One of the studies needed to insert a nasogastric tube in all patients receiving PEG, while in the remaining study, 53% of participants in the PEG group were unable to finish taking the solution whilst all the patients in the sodium phosphate

BMJ Paediatrics Open

group could complete the medication. As these were reported differently, no meta-analysis was performed. No serious adverse events were reported.

Other studies

Within the remaining studies^{1, 14-18} no meta-analysis was possible. However, no individual study found any different in adequacy of bowel preparation or adverse events. Tolerability was not well reported across studies. Whilst secondary outcome analysis for further items were planned, data was not presented to allow this to take place.

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

Discussion:

Despite the common requirement for bowel preparation in young people, the results of this review have highlighted a very poor evidence base. A mixture of clinical heterogeneity related to multiple agent regimens and methodological heterogeneity limiting the ability for meta-analysis has significantly limited synthesis. In multiple small analyses, PEG-ELS, Senna, Normal Saline, Sodium phosphate and Sodium picosulphate / Magnesium citrate found no difference in adequacy of bowel preparation. This was similar across the remaining individual studies. As such, despite the significant weaknesses of the evidence base, it is worth noting that no difference in adequacy of bowel preparation has been reported in any included study. This was also the case with adverse events, although it must be noted these were reported in an extremely heterogeneous fashion, with individual minor, major and patient overall recording of events across studies.

Of note, there was a significant difference in favour of sodium pico-sulphate and magnesium citrate regarding tolerability, specifically the need for a nasogastric tube to complete the bowel preparation. This is a particularly interesting finding, as the primary studies highlighted that whilst tolerability of PEG was extremely poor, smaller volumes than planned appeared to have little impact on efficacy. This raises the question of the need for the nasogastric tube at all and so this may need further investigation in the future. Sodium pico-sulphate was also compared to bisacodyl and a phosphate enema in a single study with equivocal preparation, tolerability and safety reported.

PEG appeared to be the least tolerable agent across all studies - with a number of the patients requiring a nasogastric tube insertion, but this is from qualitative synthesis of individual studies, with this outcome reported in heterogeneous fashion so meta-analysis was not possible. Additionally, as the age ranges of included participants varied greatly, it is hard to make firm conclusions on this finding as the need for nasogastric tubes is likely to be very age dependent. Oral sodium phosphate was well tolerated in individual studies. Despite the satisfactory tolerability and safety profile of sodium phosphate, it should be noted that care must be taken when using this agent as it can cause significant electrolyte imbalances. As such, it should not be used in patients with deranged baseline electrolytes, suboptimal renal and hepatic function, as it poses a risk of acute kidney injury and phosphate nephropathy.¹⁹

With all the agents studied the occurrence of minor adverse events such as abdominal pain, bloating, faecal incontinence, nausea, vomiting, headaches and anal irritation was comparable. No serious adverse events were reported in any of the studies. It should also be noted that in the context of elective surgery, there is growing recognition of the role for proceeding without bowel preparation.²⁰

The evidence base for this review covers a large number of trials with a reasonable number of patients, but is severely limited due to clinical and methodological heterogeneity, as well as concerns with risk of bias. As such, the findings of this review should be interpreted with extreme caution as it is difficult to draw firm conclusions for any of the investigated agents. it must also be noted that for the primary outcome, successful bowel preparation was 'as defined' by primary studies, with several different scoring systems and criteria used. This also limits the appropriateness of meta-analysis in this context, although those wishing to complete future studies should note the Ottawa scoring system²¹ was the only such scoring method reported in multiple studies. This is also true of adverse events, which were reported in a sporadic and inconsistent manner that prevented comment on even simple complaints, such as nausea or vomiting.

Considering the small sample sizes, the high degree of heterogeneity and a wide variation in the regimen of each cleansing agent; the findings of this review cannot be reliably used to inform clinical practise, but most usefully should inform future research. In particular, as the question of adequacy of bowel preparation has been established as essentially equivocal amongst all study agents, a shift of focus for future studies is needed. Given the unique needs of a paediatric population, considering the issue of tolerability as a primary outcome is vital and looking at the lower volume options presented as enteral agents could offer potential practical advantages and need a high quality study to investigate them.

Conclusions:

The publishing evidence base investigating this issue is large, but is clinically heterogeneous and at risk of bias. All regimens appear equivocal for adequacy of bowel preparation. However, when compared with sodium pico-sulphate, sodium pico-sulphate is better tolerated. Future research should seek to consider safety and tolerability, as well as efficacy, given the key importance of these issues in a childhood population.



bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright

Figure legend

Fig 1: Patient flow diagram

Fig 2: Forest plot for PEG vs Senna, adequacy of bowel preparation

Fig 3: Forest plot for Sodium picosulphate and magnesium citrate versus polyethylene glycolelectrolyte lavage solution (PEG-ELS), adequacy of bowel preparation

Fig 4: Forest plot for Sodium picosulphate and magnesium citrate versus polyethylene glycolelectrolyte lavage solution (PEG-ELS), Tolerability of agent

Fig 5: Forest plot for PEG vs Normal Saline, adequacy of bowel preparation

Fig 6: Forest plot for PEG vs Sodium Phosphate, adequacy of bowel preparation

REFERENCES

- 1. Trautwein AL, Vinitski LA, Peck SN. Bowel preparation before colonoscopy in the pediatric patient: A randomised study. *Gastroenterol Nurs* 1996;**19**:137–9.
- 2. Engum SA, Carter ME, Murphy D, Breckler FM, Schoonveld G, Grosfeld JL. Home bowel preparation for elective colonic procedures in children: Cost savings with quality assurance and improvement. J Pediatr Surg 2000;35:232-4.
- Pall H, Zacur GM, Kramer RE, et al. Bowel preparation for pediatric colonoscopy: report of the NASPGHAN endoscopy and procedures committee. J Pediatr Gastroenterol Nutr 2014;59:409-16.
- Gremse DA, Sacks AI, Raines S. Comparison of oral sodium phosphate to polyethylene glycol-based solution for bowel preparation for colonoscopy in children. J Ped Gastroenterol Nutr 1996;23:586-90.
- Hunter A, Mamula P. Bowel preparation for pediatric colonoscopy procedures. J Pediatr Gastroenterol Nutr. 2010;3:254-61.
- Terry NA, Chen-Lim ML, Ely E, Jatla M, Ciavardone D, Esch S, Farace L, Jannelli F, Puma A, Carlow D, Mamula P. Polyethylene Glycol Powder Solution Versus Senna for Bowel Preparation for Colonoscopy in Children. J Pediatr Gastroenterol Nutr 2013;56:215-9.
- Kierkus J, Horvath A, Szychta M, Woynarowski M, Wegner A, Wiernicka A, Dadalski M. High-versus Low-Volume Polyethylene Glycol Plus Laxatives versus Sennosides for Colonoscopy preparation in children. JPGN, Vol 57, 2. 2013.
- Dahshan A, Lin CH, Peters J, Thomas R, Tolia V. A Randomized, Prospective Study to Evaluate the Efficacy and Acceptance of Three Bowel Preparations for Colonscopy in Children. The American Journal of gastroenterology, (1999), 94.

- Di-Nardo G, Aloi M, Cucchara S, Spada C, Hassan C, Civitelli F, Nuti F, Ziparo C, Pession A, Lima M, Torre G and Oliva S. Bowel Preparations for Colonoscopy: An RCT. American academy of paediatrics. 2014;10:1542
- Turner D, Benchimol E, Dunn H, Griffith A.M, Frost K, Scaini V, Avolio J, Ling SC. Pico-Salax versus polyethylene glycol for bowel cleanout before colonoscopy in children: a randomized controlled trial. Endoscopy 2009;41:1038-1045.
- 11. Kumar A, Hussain A. Preoperative bowel preparation in children: polyethylene glycol versus normal saline. African journal of paediatric surgery. 2013:10; 235-238.
- Sinha K, Kanojia RP, Rawat JD, Wakhlu A, Kureel SN, Tandon RK, Verma A. Comparison of three solutions for total gut irrigation in pediatric patients. Pediatr Surg Int. 2007;23:581-584.
- Da Silva MM, Briars GL, Patrick MK, Cleghorn GJ, Shepherd RW. Colonoscopy preparation in children: safety, efficacy and tolerance of high-versus low-volume cleansing methods. J Ped Gastroenterol Nutr. 1997;24:33-7.
- 14. Pinfield A, Stringer M. Randomised Trial of two pharmacological methods of bowel preparation for day case colonscopy. Arch Dis Child. 1999; 80:181-183.
- 15. Najafi M, Hossein G, Motamed F, Farahmand F, Khodadad A, Ghajarzadeh M, Rezaei N, Mehrabani S. Comparison of one and two-day bowel preparation with polyethylene glycol in pediatric colonscopy. Turk J Gastroenterol 2015; 26: 232-5.
- 16. Sorser S, Konanki V, Hursh A, Hagglund K and Lyons H. 1-day bowel preparation with polyethylene glycol 3350 is as effective and safe as a 3-day preparation for colonscopy in children. BMC Research Notes, 7:648, 2014.
- Elitsur R, Butcher L, Vicki L, Elitsur Y. Polyethylene glycol 3350 based colon cleaning protocol: 2 d vs 4 d head to head comparison. World J Gastrointest Endosc (2013) 16; (4): 165-168.
- El-Baba M.F, Padilla M, Houston C, Madani S, Lin CH, Thomas R, Toila V. A prospective study comparing oral sodium phosphate solution to a bowel cleansing preparation with nutrition food package in children. J Pediatr Gastroenterol Nutr 2006; 42:174–177


BMJ Paediatrics Open

- 19. US Food and Drug administration (FDA). FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation.


<text><text><text>

https://mc.manuscriptcentral.com/bmjpo

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright



59 60



https://mc.manuscriptcentral.com/bmjpo

Study or Subgroup	Senn		PEC Events		Weight	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% Cl
Dahshan 1999	20	20	31	31	35.5%	1.00 [0.92, 1.08]	•
Kierkus 2013 Terry 2013	25 7	80 14	35 15	80 16	33.1% 31.4%	0.71 [0.47, 1.08] 0.53 [0.31, 0.91]	
Total (95% CI) Total events	52	114	81	127	100.0%	0.73 [0.31, 1.76]	
Heterogeneity: Tau ² =	0.56; Chi		65, df = 2	(P < 0.	00001); P	²= 95%	0.01 0.1 1 10
Test for overall effect:	Z = 0.69 (P = 0.4	9)				Favours [PEG] Favours [Senna]
				64x	14mm	(300 x 300 DF	PI)

Study or Subgrou	p Events Total Events Total Weight M-H,	
	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.00 [0.89, 1.13] 0.96 [0.75, 1.24] 0.99 [0.89, 1.11] 0.01 0.1 1 10 1 Favours [Sodium Pico] Favours [PEG-ELS]
	68x13mm ((300 x 300 DPI)

Study or Subgroup	Sodium Events		PEG EL		Woight	Risk Ratio M-H, Random, 95% CI		Ratio om, 95% CI
Di Nardo 2014 Turner 2009	1 1	75	15 30	74	48.7% 51.3%	0.07 [0.01, 0.49] 0.03 [0.00, 0.22]	← ■	011, 95% CI
Total (95% CI)		121			100.0%	0.04 [0.01, 0.18]		
Total events Heterogeneity: Tau ² = Test for overall effect				= 0.60);	I² = 0%		0.01 0.1	10 10
	2 - 4.00 (017				Favours [Sodium Pico]	Favours [PEG-ELS]
				68x	(13m	m (300 x 300	DPI)	
				007	1.5111	III (300 × 300		

bmjpo: first published as 10.1136/bmjpo-2017-000118 on 18 September 2017. Downloaded from http://bmjpaedsopen.bmj.com/ on April 26, 2024 by guest. Protected by copyright.

1 2 3					
4 5					
6 7		rmal saline PEG ents Total Events	Risk Rati Total Weight M-H, Random,		
8	Kumar 2013 Sinha 2007	14 15 15 37 40 53	15 24.2% 0.94 [0.7 55 75.8% 0.96 [0.8	8, 1.12]	
9 10	Total (95% CI)	55	70 100.0% 0.95 [0.8		
11	Total events Heterogeneity: Tau² = 0.00	51 68 D; Chi ² = 0.06, df = 1 (P =	0.81); I ^z = 0%	0.7 0.85 1	1.2 1.5
12	Test for overall effect: Z = 1	1.04 (P = 0.30)			Favours [Normal saline]
13 14					
15					
16 17			67x12mm (300 x 3	300 DPI)	
18					
19					
20 21					
22					
23 24					
25					
26					
27 28					
29					
30					
31 32					
33					
34 35					
36					
37					
38 39					
40					
41 42 43					
43					
44					
45 46					
47					
48 49					
50					
51					
52 53					
54					
55 56					
57					
58					
59 60					

Ctudu or Cub	NaP	Total	PEG	atel	Mainh	Risk Ratio	Risk Ratio
Study or Subgroup Da Silva 1997 Gremse 1996	Events 10 18	Total 15 19	11 11 8	otal 15 15	50.4% 49.6%	M-H, Random, 95% CI 0.91 [0.57, 1.45] 1.78 [1.09, 2.89]	M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect	28 0.17; Chi ^a	34 = 3.81,	19 df=1 (P	30	100.0%	1.27 [0.66, 2.45]	0.1 0.2 0.5 1 2 5 Favours [NaP] Favours [PEG]
			6	4x:	13mm	ı (300 x 300 DF	PI)

60

1

Appendix 1 - Search strategy

vid EMBASE 1974 to 16 July 2016

- $1. \ exp \ colonoscopy/ \ OR \ colonoscop*.mp.$
- 2. Surgery OR procedure
- 3. 1 or 2
- 4. infant/
- 5. child/
- 6. school child/
- 7. adolescent/

8. (infant* or child* or pediatric* or paediatric* or adolescent* or neonat* or toddler or young).mp.

- 9. 4 or 5 or 6 or 7 or 8
- 10. colon lavage/
- 11. intestine preparation/
- 12. exp laxative/
- 13. exp macrogol derivative/
- 14. exp phosphate/
- 15. exp citric acid/
- 16. exp magnesium oxide/
- 17. exp bisacodyl/
- 18. exp organometallic compound/
- 19. exp sulfate/
- 20. exp anthraquinone derivative/
- 21. exp enema/

22. (cathartic* or polyethylene glycol* or laxative* or phosphate* or citrate* or magnesium oxide* or bisacodyl or organometallic compound* or sulfat* or anthraquinone* or enema or bowel preparation or bowel cleansing or PEG-ELS or macrogol* or senna or docusate sodium or Sodium picosulphate or Cascara or casanthranol or Buckthorn or senokot or Aloe Vera or aloin Phenolphthalein or Dulcolax or stimulant or osmotic).mp.

23. (Miralax or Transipeg or Movicol or Forlax or Idrolax or GoLytely or PMF-100 or Golitely or Nulitely or Fortans or TriLyte or Colyte or lactulose or disaccharide or Apo-Lactulose or Chronulac or lactitol or sorbitol or Generlac or Cephulac or Cholac or Constilac or Enulose or Cilac or Heptalac or Actilax or Duphalac or Kristalose or Citroma or Osmoprep or Visicol).mp.

24. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23

- 25. 3 and 9 and 24
- 26. CROSSOVER PROCEDURE.sh.
- 27. DOUBLE-BLIND PROCEDURE.sh.
- 28. SINGLE-BLIND PROCEDURE.sh.
- 29. (crossover* or cross over*).ti,ab.
- 30. placebo*.ti,ab.
- 31. (doubl* adj blind*).ti,ab.
- 32. allocat*.ti,ab.
- 33. trial.ti.
- 34. RANDOMIZED CONTROLLED TRIAL.sh.
- 35. random*.ti,ab.
- 36. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
- 37. (exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans or man or men or wom?n).ti.)